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ABSTRACT  
 
Human T-Lymphotropic virus type 1 (HTLV-1) is the causative agent of two distinct 
pathologies, adult T-cell leukemia (ATL), an aggressive malignancy of mature 
CD4+ T-cells, and tropical spastic paraparesis/HTLV-1-associated myelopathy 
(TSP/HAM), a demyelinating neurodegenerative disease. An estimated 10–20 
million people worldwide are infected with HTLV-1. While the majority of HTLV-1-
infected individuals remain asymptomatic, a low percentage of patients develop 
either ATL (3–5%) or TSP/HAM (0.3–2%) after a long period of clinical latency. 
HTLV-1 primarily infects CD4+ T-cells and has been detected in ex vivo CD8+ T- 
cells, B-cells, monocytes and dendritic cells (DC) from infected individuals. These 
cells may contribute, more than previously thought, to viral persistence and 
pathogenesis. DCs isolated from HTLV-1-positive patients are defective in IFN-α 
response upon in vitro stimulation and their ability to activate T-cells is impaired. In 
addition, in HTLV-1 infected patients alteration in monocytes differentiation and 
activation has been reported. Contrarily to how observed in T or B cell, where 
HTLV-1 p30 is not required in vitro for an efficient viral replication, p30 seems to 
play a key role during HTLV-1 infection of DCs. In the macaque model, the ablation 
of p30 expression within the HTLV-1 provirus (p30-KO) or p12/p8 (p12-KO) 
severely affects infectivity. Furthermore, the infectivity of p30-KO in human primary 
monocyte-derived dendritic cells (Mo-mDCs) is severely impaired and is not 
sustained over time. Prior data demonstrated that p30, by interacting with the 
cellular transcription factor PU.1 in human monocytes, affects TLR4 signaling and 
the expression of several genes involved in apoptosis, cell cycle, and transcription, 
pointing to p30 as a regulator of innate response to HTLV-1. The interaction of p30 
and PU.1 might lead to inhibition of the transcriptional activity of PU.1.  
We used a human monocytic cell line, THP-1 and primary dendritic cells, to study 
the mechanism of p30 and p12/p8 requirement in these cell types. We 
hypothesized that p30 and/or p12/p8 affected not only TLR3/4 but also TLR7/8 
signaling in virus infected monocytes and in dendritic cells, and that by affecting the 
type 1 IFN response p30 and/or p12/p8 affects the activation and differentiation of 
these cells and ultimately the host response to the virus allowing viral replication 
and spread throughout the body.  
We confirm that p30 decreases the expression of TLR4 on THP-1 surface and the 
production of IL12 and TNFα by these cells. p30 is also able to inhibit the 
expression of interferon responsive genes (ISG) following stimulation with LPS of 
the TLR4 and with polyI:C of TLR3, but not of TLR7/8 with Imiquimod. Results 
in THP-1 mirrored those in ex-vivo human primary monocyte-derived dendritic cells 
(Mo-mDC). The effect of p30 on TLRs signaling was also demonstrated by ablating 
its expression within a molecular clone of HTLV-1. HTLV-1 infection of 
monocytes inhibited TLR3 and TLR4–induced ISGs expression by 50 to 90%, 
depending on the genes, whereas the isogenic clone p30 knockout (KO) virus was 
less effective in inhibition of TLR3 and TRL4 signaling and displayed lower 
infectivity. Viral expression and inhibition of ISGs transcription, was however, 
rescued by restoration of p30 expression. A chromatin immunoprecipitation (ChIP) 
assay demonstrated that p30 inhibits initiation and elongation of PU.1 dependent 
transcription of interferon-α1 (IFNα1), IFNβ, and TLR4 genes upon TLRs 
stimulation. In contrast, experiments conducted with p12/p8 did not demonstrate an 
effect on IFN response gene expression. These results provide a mechanistic 
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explanation on the requirement of p30 for HTLV-1 infectivity in vivo, and suggest 
that dampening interferon responses in monocytes and DCs is specific for p30 and 
represent an essential early step for permissive HTLV-1 infection and persistence.  
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SOMMARIO 
HTLV-1 (Human T-lymphotropic virus type 1), o Virus T-linfotropico dell'uomo di 
tipo 1 e’ un retrovirus oncogene scoperto nel 1979. HTLV-1 è causa di due distinte 
patologie: la leucemia dell'adulto a cellule T (ATL), un tumore maligno molto 
aggressive che colpisce I linfociti T CD4+ maturi, e la paraparesi spastica 
tropicale/mielopatia associata ad HTLV-1 (TSP/HAM), una malattia 
neurodegenerative demielinizzante. Circa 10-20 milioni di persone sono infette con 
HTLV-1; tuttavia, la maggior parte di esse rimane asintomatica e solo una bassa 
percentuale di pazienti sviluppa la malattia dopo un lungo periodo di latenza clinica 
(nel 3-5% ATL e nel 0.3-2% TSP/HAM).  
I linfociti T CD4+ sono le cellule target inizialmente infettate da HTLV-1. Il virus, 
tuttavia, e’ stato ritrovato ex vivo anche nei linfociti T CD8+, nei linfociti B, nei 
monociti e nelle cellule dendritiche di pazienti infetti. Queste cellule potrebbero 
contribuire, piu’ di quanto finora si pensava, all’infettivita’, alla persistenza e alla 
patogenesi del virus. Diversi studi hanno dimostrato che cellule dendritiche (DC) di 
pazienti HTLV-1 positivi hanno una ridotta capacita’ di attivare I linfociti T e una 
diminuita produzione di IFN-α in vitro. Inoltre e’ stato osservato che in pazienti 
HTLV-1 infetti si ha spesso un’alterazione nel differenziamento e nell’attivazione 
dei monociti. 
Contrariamente a quanto osservato nei linfociti T e B, nei quali la proteina virale di 
HTLV-1 p30 non e’ risultata necessaria per ottenere un’efficiente replicazione virale 
in vitro, p30 sembra giocare un ruolo chiave durante l’infezione da parte di HTLV-1 
di DC. Nel modello animale (Rhesus macaque), la delezione  delle proteine virali 
p30 o p12/p8 causa una diminuzione dell’infettivita’ dei virioni. Risultati simili sono 
stati osservati anche in cellule dendritiche umane infettate in vitro con cloni 
molecolari di HTLV-1 privati dell’espressione di p30.  
Dati precedenti hanno dimostrato inoltre che p30, interagendo con il fattore 
trascrizionale PU.1 nei monociti, influenza il pathway di signaling del TLR4 e 
l’espressione di diversi geni coinvolti nell’apoptosi, nel ciclo cellulare e nella 
trascrizione. L’interazione tra le due protein p30 e PU.1 potrebbe portare 
all’inibizione dell’attivita’ trascrizionale di quelst’ultima. 
Per studiare la funzione di p30 e p12/p8 in questo studio abbiamo usato una linea 
cellular monocitica umana (THP-1) e cellule dendritiche umane primarie. Abbiamo 
ipotizzato che p30 e/o p12/p8 possano influenzare sia il pathway di signaling di 
diversi TLR (TLR3, 4, 7 e 8) sia la risposta antivirale mediate dagli interferoni di 
tipo 1 nei monociti e nelle cellule dendritiche HTLV-1 infette e possano quindi 
permettere la replicazione virale e la diffusione del virus nel corpo. 
Abbiamo inizialmente confermato, come dimostrato da dati pubblicati 
precedentemente, che p30 downregola l’espressione del TLR4 sulla superficie 
delle THP-1 e la produzione di IL12 e TNFα da parte delle stesse cellule. p30 e’ 
anche in grado di inibire l’espressione di geni responsive agli interferoni (ISG) in 
seguito a stimolazione del TLR4 con LPS, del TLR3 con polyI:C; ma non del 
TLR7/8 con Imiquimod. I risultati ottenuti con le cellule dendritiche umane derivate 
dai monociti (mdDC) sono simili a quelli descritti per le THP-1. L’effetto di p30 sul 
pathway di signaling dei TLR e’ stato anche confermato deletando l’espressione 
della proteina virale in un clone molecolare di HTLV-1. Mentre l’infezione dei 
monociti da parte del virus wild type inibiva l’espressione di ISG nel 50-90% dei 
casi in base al gene analizzato; il clone molecolare virale che non esprime la 
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proteina p30 ha mostrato una minor capacita’ di inibizione del signaling dei TLR3 e 
4 e quindi dell’espressione di ISG e una conseguente minore capacita’ di infezione. 
Riaggiungendo alla coltura la proteina p30, l’espressione del virus e degli ISG e’ 
tornata ai livelli precedentemente osservati (rescue). Mediante un saggio di 
immunoprecipitazione cromatinica (ChIP) e’ stato dimostrato che p30, dopo 
stimolazione dei TLR, inibisce sia l’inizio, sia l’allungamento della trascrizione di 
geni sotto il controllo di PU.1 quali IFNα1, IFNβ, e TLR4. 
Questi risultati suggeriscono che la proteina virale p30 sia da ritenere 
fondamentale per l’infettivita’ del virus in vivo e suggeriscono che p30 sia 
responsabile di una downregolazione della risposta antivirale mediate dagli 
interferoni nei monociti e nelle cellule dendritiche e che questo fatto rappresenti 
uno degli step fondamentali perche’ si instauri un’infezione da HTLV-1 persistente.   
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1. INTRODUCTION 
1.1 Human T-lymphotropic virus type 1: taxonomy, 
epidemiology and pathogenesis 
Human T-cell leukemia/lymphoma virus type-1 (HTLV-1) is the first 
retrovirus discovered in 1979 in T-lymphocytes of a patient with cutaneous 
T-cell lymphoma [1; 2]. This retrovirus is able to establish a persistent 
infection in humans and is the only one with oncogenic properties [3].  
HTLV-1 belongs to the Retroviridae family, Oncovirinae sub-family, 
Deltaretrovirus genus, which also includes HTLV-2, -3, -4, simian T-
Lymphotropic virus (STLV), and bovine leukemia virus (BLV). STLV and 
BLV infections are associated with neoplastic diseases, while the 
pathogenicity of HTLV-2, -3, -4 has not been clearly established [4; 5; 6]. 
Deltaretroviruses have two main peculiarity: they present at the 3’ end of 
the genome, the “pX region” that encodes the regulatory proteins Tax and 
Rex and different accessory proteins. Another characteristic of the 
Deltaretroviruses is represented by their oncogenic mechanism of cell 
transformation, which does not involve the expression of a cellular-derived 
viral oncogene (v-onc), as in the case of acute-transforming retroviruses, or 
integration in the proximity of a cellular proto-oncogene (c-onc), as in the 
case of chronic-transforming retroviruses. The mechanism of cell 
transformation by Deltaretroviruses is instead determined by the ability of 
Tax protein to de-regulate the expression of a wide range of cellular genes.  
HTLV-1 primarily infects CD4+ T-cells and has been detected in ex vivo 
CD8+ T-cells, dendritic cells (DC), and B-cells from infected individuals. 
While cell-free virions have been shown to efficiently infect DCs in vitro, 
HTLV-1 is believed to be transmitted to T-cells and DCs mostly by cell-to-
cell contact through a virological synapse, biofilm-like extracellular viral 
assemblies, or cellular conduits [7; 8; 9; 10].  
Based on epidemiology studies it has been estimated that approximately 15 
to 20 million HTLV-1 carriers exist throughout the world [11]. This virus is 
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endemic in South-Western Japan, Central Africa, the Caribbean Basin, 
Central and South America and the Melanesian Islands. Sporadic infection 
occurs in Europe and North America. In these endemic areas there is a 
wide range of seroprevalence rates ranging from 0.1 to 30%. HTLV-1 is 
spread through contact with bodily fluids containing infected cells. 
Contaminated whole blood or whole blood products represent the most 
common form of HTLV-1 transmission in the United States of America, 
typically from sharing of needles among intravenous drug users [12; 13; 14] 
or transfusion of infected blood products. However the more natural route 
of HTLV-1 transmission is through infected mothers who breast-feed their 
children resulting in the transfer of infected maternal lymphocytes to their 
infant [ 15 ]. Japan has educated HTLV-1 infected mothers about the 
possible risks of transmitting HTLV-1 through breast-feeding, effectively 
reducing transmission in endemic regions [16;17]. Perinatal contamination 
of the fetus from infected maternal blood occurs, but does not represent a 
significant mode of HTLV-1 transmission [18]. The transmission of HTLV-1 
through sex is a less efficient route of transmission, however male to 
female transmission via semen is four-times as likely to lead to 
transmission as female to male [19].  
While the majority of HTLV-1-infected individuals remain asymptomatic, a 
low percentage of patients develop after prolonged latency periods (as long 
as 20 to 60 years) two major diseases: adult T-cell leukemia (ATL), a 
disease characterized by malignant proliferation of CD4+ T-lymphocytes, 
and tropical spastic paraparesis/HTLV-1-associated myelopathy 
(TSP/HAM), a neurodegenerative disorder [20; 21; 22; 23; 24; 25; 26]. In 
spite of over 30 years of study, the molecular mechanisms determining ATL 
or TSP/HAM have not been yet fully clarified. HTLV-1 is also associated 
with other clinical disorders including HTLV-1-associated arthropathy, 
HTLV-1-associated uveitis [ 27 ; 28 ], infective dermatitis [ 29 ], and 
polymyositis [30;31]. 
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1.2 Human T-lymphotropic virus type 1 associated diseases 
As mentioned before, HTLV-1 is causatively associated with a number of 
pathologies; the two most common are adult T-cell leukaemia (ATL) and 
HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP).  
Only a minority of HTLV-1-infected individuals develops disease. 
Depending on ethnicity and gender, approximately 2–3% of infected 
individuals develop ATL and 0.25–4% develop HAM/TSP [32;33;34]. Other 
associated diseases include HTLV-associated uveitis and infective 
dermatitis. The majority of infected individuals remain lifelong asymptomatic 
carriers (ACs). The mechanisms by which HTLV-1 causes such diverse 
clinical diseases are not understood and it is also not known why disease 
typically occurs decades after initial infection and affects less than 10% of 
carriers. Understanding of HTLV-1-associated disease is further limited by 
the lack of suitable animal models and inaccessibility of tissue from the 
central nervous system of individuals. Since no viral genotype has been 
associated with any particular disease [35] and there is a large antiviral 
immune response, the currently accepted hypothesis is that the host 
immune response is the main determinant of the risk of disease [36;37]. 
1.2.1 Adult T-cell leukemia (ATL) 
Adult T-cell leukemia/lymphoma, in its acute form, is an aggressive T-cell 
malignancy that typically occurs 20 to 30 years after infection with HTLV-1 
[16]. Neoplastic disease associated with HTLV-1 is exhibited in a variety of 
clinical forms, but is characterized by a monoclonal population of T-cells 
that express CD3+/CD4+/CD8−/CD25+/HLA-DR+ cell surface markers [17–
19], which frequently accumulate in peripheral blood as well as in lymphoid 
organs and skin.  
Clinically, ATL occurs in at least four different forms: (1) smoldering; (2) 
chronic; (3) lymphoma and (4) acute [17]. Patients afflicted with the acute 
form of ATL make up approximately 55 to 75% of all ATL cases and 
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present with fever, malaise, skin lesions, lymphadenopathy, leukocytosis 
and hepatosplenomegaly. 
 
Type of ATL Characteristics 
ACUTE In individuals with acute ATLL, symptoms develop 
rapidly and may include fatigue, skin rash, and 
enlarged lymph nodes in the neck, armpit, or groin. 
The hallmarks of acute ATLL are a high white blood 
cell count often accompanied by an elevated level of 
calcium in the blood (hypercalcemia), which can 
cause irregular heart rhythms and severe constipation. 
Patients present also organomegaly and high lactate 
dehydrogenase (LDH). 
CHRONIC This slow-growing type of ATL can result in elevated 
lymphocytes in the blood, enlarged lymph nodes, skin 
rash, or fatigue. It can also be found in other areas of 
the body such as the spleen and liver. Patients 
present lymphocytosis >4x109/L with ATL cells, skin, 
lung, liver or node involvement, normal calcium level, 
LDH normal or less that twice in upper normal limit. 
SMOLDERING This slow-growing type of ATL is associated with very 
mild symptoms, such as a few skin lesions. Skin 
and/or lung infiltrating and no other organ 
involvement. Patients present normal lymphocyte 
count (1-5% ATL cells), normal calcium and LDH. 
LYMPHOMATOUS This subtype of ATLL is found primarily in the 
lymphnodes. Patients present organomegaly. Less 
than 1% circulating leukemia cells, high LDH and 
possible hypercalcaemia. 
TABLE 1: the four subtypes of ATLL: acute, lymphomatous, chronic, and 
smoldering. Acute and lymphomatous are fast-growing forms of ATLL, 
whereas chronic and smoldering are less aggressive. 
 
Depending on the subtype, diagnosing ATLL may require removing a small 
sample of tumor tissue or abnormal skin tissue (biopsy). A blood test may 
also be necessary to measure the white blood cell count and calcium 
levels. Other tests, such as a bone marrow biopsy, a computed axial 
tomography (CAT) scan of the chest, abdomen, liver, and spleen, and/or a 
positron emission tomography (PET) scan may be used to determine if, or 
how far, the cancer has spread.  
 In some cases the acute phase of ATL
lymphocytosis characterized by poly
genome. The prolonged and complex interactions between the host and the 
virus that lead to development of ATL have not been elucidated. HTLV
infected neoplastic monoclonal T
of infected T-cells. Selective pressures such as the anti
immune response of an infected individual promote an oligoclonal 
population of infected T-cells with survival adva
oligoclonal population, a neoplastic T
variety of somatic genetic mutations. 
driven by the expression of proviral genes (Tax/ HBZ) counter
the HTLV-1-specific immune response. Clones that become long lived may 
undergo genetic damage and subsequent malignant transformation [
These cells possess multi-lobulated nuclei and are called "flower cells"
(Figure 1).  
Figure 1: Typical "flower cell" in t
patient. (Matsuoka 
Furthermore, HTLV-1 infection is accompanied by a high frequency of T
cells expressing the surface marker Forkhead Box P3 (FoxP3) [
6
 is preceded by peripheral 
- or oligoclonal integration of the viral 
-1 
-cells originate from polyclonal populations 
-HTLV-1 adaptive 
ntages to emerge. From this 
-cell clone emerges typically with a 
Clonal expansion is thought to be 
-balanced by 
38]. 
 
 
he peripheral blood of an acute ATL 
et al. 2005) 
 
-
39;40], 
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which play a critical role in suppressing the immune response. The 
increase in FoxP3+ cell frequency in HTLV-1 infection results from the 
upregulation of the CCL22 chemokine production by HTLV-1-infected cells 
that express Tax. CCL22 engages the CCR4 receptor expressed on the 
functional T regulatory (Treg) cell population, resulting in an enhancement 
of the migration and survival of FoxP3+ cells in vitro. These FoxP3+ cells 
may both retard the progression of ATL and HTLV-1-associated 
inflammatory diseases and contribute to the immune suppression seen in 
HTLV-1 infection, especially in ATL [41]. 
Until recently the protein Tax was considered to be critical both for 
leukemogenesis and viral persistence because of its interactions with host 
genes responsible for cell proliferation, DNA repair, cell cycle control, and 
apoptosis [42] and because of its associations with cell proliferation in vitro 
[43] and in vivo [44]. However, Tax expression is only detected in about 
30% of freshly isolated samples from ATL cases. Tax expression can be 
disrupted by deletion or CpG hypermethylation of the 5’LTR leading to 
silencing of forward strand transcription [45] and genetic mutations in Tax 
itself leading to silencing. These findings rise up doubt on the hypothesis 
that continued expression of Tax is essential in the late stages of 
leukaemogenesis [46;47]. In contrast to Tax, HTLV-1 bZIP factor (HBZ) 
mRNA has been detected in 100% of ATL cells [48;49]. Anyway, current 
opinion favors the role of Tax in the initiation of ATL and HBZ to maintain 
the transformed phenotype. 
1.2.2 HTLV-1 associated myelopathy/tropical spastic paraparesis 
(HAM/TSP) 
In 1985, Gessain et al. reported that a group of HTLV-1-seropositive 
patients in French Martinique suffered from a neurodegenerative disorder 
called tropical spastic paraparesis (TSP). Osame et al. subsequently 
described a similar clinical disorder in Japanese patients and termed it 
HTLV-1 associated myelopathy (HAM). TSP/HAM is characterized by a 
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slowly progressive spastic paraparesis, associated with bladder dysfunction 
and sensory disorders. The onset of HAM/TSP typically occurs in younger 
subjects infected with HTLV-1 and is more closely linked to the transfusion 
of HTLV-1 infected blood products, whereas ATL has been linked to 
transmission through breast milk of infected mothers. Parenchymal and 
perivascular infiltration of HTLV-1 specific CD4+ and CD8+ T lymphocytes 
occurs in the white and gray matter of the spinal cord, resulting in severe 
inflammation from production of pro-inflammatory cytokines such as IL-1, 
IL-6, IFN-γ, and TNF-α. Accumulation of pro-inflammatory cytokines leads 
to demyelization fibrosis and lymphocytic meningomyelitis [ 50 ]. The 
presence of infiltrating T-cells in the spinal cord lesions and of Tax-specific 
cytotoxic T- lymphocytes (CTL) in the cerebrospinal fluid and in the 
peripheral blood mononuclear cells (PBMCs) suggests that TSP/HAM 
might have an autoimmune base [51;52]. This hypothesis is consistent with 
the association between HLA haplotype and the risk of developing 
TSP/HAM [53]. 
The detailed mechanism of HAM/TSP development like ATL has yet to be 
elucidated. However HTLV-1 proteins utilizing molecular mimicry or acting 
as auto antigens have been postulated as factors that contribute to the 
development of HAM/TSP. Risk factors for the development of HAM/TSP 
such as high proviral loads have been linked with the development of 
HAM/TSP. 
 
 
TSP/HAM CLINICAL CHARACTERISTICS 
Spasticity lower extremities, hypereflexia, muscle weakness, and 
sphincter disorders, including dysfunction of the urinary bladder and 
intestines; clinically may overlap with multiple sclerosis  
Progressive chronic myelopathy, with preferential damage of the 
thoracic spinal cord  
 
Early lesion development characterized by infiltrates composed 
predominantly of CD4+ T-cells, and macrophages with detectable levels 
of HTLV-1 tax RNA in lesions  
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Characterized by multiple white matter lesions in both the spinal cord 
and the brain involving perivascular demyelination and axonal 
degeneration; rarely, cerebellar syndrome with ataxia and intention 
tremor  
 
Late lesions (>4 years) predominantly CD8+ T-cells with less tax RNA  
 
Cerebrospinal fluid contain high levels of pro-inflammatory cytokines, 
including IFN- γ, TNF-α, IL-1, and IL-6, as well as increased numbers of 
activated lymphocytes  
 
 
TABLE 2: HTLV-1-Associated Myelopathy/ Tropical Spastic Paraparesis 
(HAM/TSP). 
1.2.3 Other disorders associated with HTLV-1 infection 
A number of other immune-mediated chronic inflammatory conditions are 
associated with HTLV-1 infection. However, it is less clear what specific 
role HTLV-1 infection plays in the initiation or development of these 
diseases. Arthropathies, uveitis, infective dermatitis, polymyositis, chronic 
respiratory disease, Sjogren’s syndrome, lymphadenitis, and certain acute 
myeloid leukemias have been associated with HTLV-1 infection. It has 
been hypothesized that the deregulation of the immune system in chronic 
HTLV-1 infection promotes diseases. HTLV-1 related uveitis are 
characterized by infiltration of HTLV-1-infected lymphocytes and 
deregulated production of cytokines. Increased proviral load found in 
patients with HAM/TSP and uveitis results from clonal expansion of the 
HTLV-1-infected T-cells, which has been implicated in the pathogenesis of 
HTLV-1-associated diseases [54]. 
1.3 Infection and virus propagation 
HTLV-1 is an enveloped virus that contains two identical copies of a plus 
single-stranded RNA genome that carries genetic information for structural 
proteins and enzymes (Gag, Env, reverse transcriptase (RT), protease, 
integrase) and is surrounded by capsid and matrix proteins and by an outer 
lipoproteic envelope containing protruding viral glycoproteins gp21 and 
gp46 (Figure 2) [55;56]. HTLV-1 can infect a wide range of human cell 
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types in vitro (monocytes, microglial cells, epithelial cells, B- and T- 
lymphocytes), but in vivo the virus is almost confined to the CD4+ T 
lymphocyte subset [57]. CD8+ T lymphocytes can also carry the virus, but at 
a consistently lower frequency than CD4+ T cells. Viral spread is mediated 
through the interaction between the viral envelope protein gp46 and the 
glucose transporter GLUT-1 [57]. Consequently, glucose consumption of 
the infected target cell is inhibited and extracellular ambient acidification is 
reduced, possibly causing metabolic alterations in the infected cells [55; 
57]. The gp46-GLUT-1 interaction allows the envelope protein gp21 to 
mediate cellular membranes fusion with the formation of the “virological 
synapse” which may be defined as a virus-induced, specialized area of cell-
to-cell contact that promotes the directed transmission of the virus between 
cells. Its assembly results from the polarization of the cytoskeleton of the 
infected cell and the accumulation of HTLV-1 core complexes and the 
HTLV-1 genome at the cell junction; the virion components are then 
transferred to the uninfected cell as enveloped particles [58;59]. Tax is 
involved in the formation of the virological synapse: it localizes in the 
contact region between infected and target cells [60] and enhances MTOC 
(microtubule organizing center) formation by stimulating the CREB pathway 
[61]. Proteins that mediate antigen recognition and cell adhesion (e.g. hDlg, 
neuropilin-1, heparan sulphate proteoglycans) also contribute to HTLV-1 
binding and entry into the target cell and are part of the "virological 
synapse" [62;63;64].  
Another mode of HTLV-1 transmission is mediated through an extracellular 
biofilm-like structure that stores viral particles, facilitating virus spread after 
cell-to-cell contact [65]. Both the virological synapse and biofilm-mediated 
transmission are consistent with the fact that cell-free HTLV-1 particles are 
usually undetectable in the serum of HTLV-1 infected subjects [66; 67]. 
After virus entry into the target cell, the viral genome is reverse-transcribed 
by viral reverse transcriptase (RT), producing an RNA-DNA hybrid. The 
 11 
ribonuclease H (RNAse H) component of viral RT degrades the RNA 
strand, while the DNA strand is used as a template by RT. RT also has 
DNA-polymerase-DNA-dependent activity, to synthesize a complementary 
DNA strand. The double-stranded DNA circularizes and transfers to the 
nucleus, where it integrates randomly in the host genome. Integration is 
mediated by the viral enzyme integrase and by the long terminal repeats 
(LTRs) located at both ends of the viral genome. Viral genes are then 
transcribed and translated by the cellular machinery. Virion assembly 
occurs in the cytoplasm, through the interaction between the viral 
nucleocapsid and the plasma membrane, and incorporation of two copies 
of the single stranded RNA genome along with tRNA, RT, protease and 
integrase.  
 
 
Figure 2. Schematic representation of the HTLV-1 virion (Lairmore et al. 
2012). 
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1.3.1 HTLV-1 target cells 
T-cells have been considered the key target cells for HTLV-1 infection, as 
the virus is almost always present in the ATLL cells and is found in the T-
cells of TSP/HAM patients. However, whether cells other than T-cells also 
contribute to the pathogenesis of HTLV-1 infection remains unclear. 
Indeed, HTLV-1 also infects monocytes/macrophages and dendritic cells 
[7;12], that are professional antigens presenting cells and shape the host 
response to viruses as well as to other pathogens. DCs isolated from 
HTLV-1-positive patients are defective in IFN-α response upon in vitro 
stimulation and their ability to activate T-cells is impaired. In addition, 
several studies suggest that impairment of DC function after HTLV-1 
infection plays a part in pathogenesis [7]. In addition, in HTLV-1 infection, 
alteration in monocytes differentiation and activation has been reported. 
Although the majority of HTLV-1 DNA is found in both CD4+ and CD8+
 
T-
cells, up to 20 % of the total virus burden is found in monocytes (our 
unpublished data). 
Cell-free human T-lymphotropic virus type 1 (HTLV-1) virions are poorly 
infectious in vitro for their primary target cells, CD4+ T cells, efficient viral 
spread instead requires direct cell-to-cell contact. HTLV-1 can efficiently 
infect in a cell free manner myeloid and plasmacytoid dendritic cells (DCs). 
Moreover, DCs exposed to HTLV-1, both before and after being 
productively infected, can rapidly, efficiently and reproducibly transfer virus 
to autologous primary CD4+ T cells. This DC-mediated transfer of HTLV-1 
involves heparan sulfate proteoglycans and neuropilin-1 and results in long-
term productive infection and IL2–independent transformation of the CD4+ 
T cells. So we can say that DCs have a central role in HTLV-1 
transmission, dissemination and persistence in vivo [7].  
1.4 HTLV-1 genetic organization 
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The genome of HTLV-1 is approximately 9032 nucleotides long and it 
contains the typical retroviral structural and enzymatic genes Gag, Pro, Pol, 
and Env [68]. In addition, a region located between Env and the 3' long 
terminal repeat (LTR), contains four partially overlapping open reading 
frames (ORF) and is termed the pX region. This unique region encodes 
several regulatory and non-structural proteins through the use of alternative 
splicing and internal initiation codons [69; 70; 71].  
Orf-I produces the p12 protein which can be proteolytically cleaved at the 
amino terminus to generate the p8 protein, while differential splicing of 
mRNA from Orf-II results in production of the p13 and p30 proteins [71; 72]. 
Orf-III and Orf-IV encode for the Rex and Tax proteins, respectively, and an 
antisense mRNA transcribed from the 3' LTR that generates the HTLV-1 
basic leucine zipper (HBZ) protein [73; 74; 75]. Expression of the highly 
condensed HTLV-1 genetic information is achieved through ribosomal 
frame shifting (which generates a Gag-Pro-Pol polyprotein from the full-
length transcript), by alternative splicing and polycistronic translation (which 
produces distinct mRNAs coding for the Env and pX region genes) and 
through minus-strand transcription, which generates at least 2 different 
transcripts encoding 2 isoforms of the HBZ protein (Figure 3).  
 
 Figure 3. A scheme of the human T
(HTLV-1) genome. (A) Plus-strand ORFs, transcriptional map and proteins 
coded by each mRNA are shown. The numbering indicates splicing sites 
used for the generation of the mature mRNAs. 
and p8 proteins. The p30 protein is translated from doubly sp
transcribed from Orf-II and the 5' end of E
from singly spliced mRNA transcribed from O
carboxyl terminus of p30. (B) For the minus
14 
 
-cell leukemia/lymphoma virus type-1 
Orf-I encodes for the p12 
liced mRNA 
nv. The p13 protein is translated 
rf-II and corresponds to the 
-strand, the ORF, transcriptional 
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map and proteins coded by each mRNA are shown. The numbering 
indicates the start sites used for the generation of the mature mRNAs. 
Resulting exons are: hbz us and hbz sp1. 
1.4.1 Expression of structural proteins 
The full-length HTLV-1 mRNA (8.6 kb) is packaged into virions and is also 
translated into the structural proteins (Gag) and enzymes (Protease and 
Polymerase) of mature virus particle. HTLV-1 Gag or p55 is produced as a 
single precursor polyprotein. The Gag gene codes for the 19 kDa matrix 
(MA), 24 kDa capsid (CA) and 15 kDa nucleocapsid (NC) structural 
proteins. The pro gene encodes the viral protease. The 5' portion of the Pol 
gene encodes the reverse transcriptase protein, which converts the viral 
single-stranded RNA genome into double stranded DNA through its DNA 
polymerase and RNaseH activities. Sequences downstream code for 
Integrase, which is responsible for the integration of the reverse-transcribed 
viral genome in the host cell genome. 
These genes are translated as polyproteic precursors (Gag, Gag-Pro and 
Gag-Pro- Pol) generated through ribosomal frameshifting at the gag-pro 
and/or gag-pro-pol junction (Figure 4).  
 
 
Figure 4. Schematic representation of the Gag-Pro-Pol polyprotein 
precursors of HTLV-1. Fs1 and fs2: ribosomal frameshifting sites; MA: 
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matrix, CA: capsid; NC: nucleocapsid, PRO: protease, RT: reverse 
transcriptase (Le Blanc et al., 2001). 
 
The polyprotein is myristylated, post-translationally, and targeted for the 
inner lipid plasma membrane of the cell. At the inner membrane of the 
plasma membrane Gag is cleaved by viral proteases into its functional 
units: CA, NC and MA. Capsid interacts with itself to form the inner core of 
the virion. Nucleocapsid interacts with the genomic RNA inside the inner 
core of the virion. The proper spatial and temporal events of viral assembly 
and budding play a critical role in the ability of HTLV-1 to be transmitted 
from one cell to another. In contrast to HIV-1 Gag, the interaction of HTLV-
1 MA appears to be independent of plasma membrane phospholipid, 
phosphatidylinositol-(4,5)-bisphosphate used by HIV-1 in particle assembly. 
HTLV-1 MA contains a PPPY domain that assists in virus budding by 
targeting cellular proteins Nedd4.1 and Tsg101. In addition to assisting in 
virus budding and assembly, MA appears to have a role in cell-to-cell 
transmission of the virus. Thus, like other retroviruses, phosphorylation of 
HTLV-1 L-domain proteins appears to be important in regulation of viral 
budding and thus cell-to-cell transmission. In addition, HTLV-1 uses a C-
terminal peptide region of NC to block the action of the host restriction 
factor ABOBEC3G. Protease is produced from ribosomal frame shifting 
initially as an immature form that is inactive until self-cleavage activates the 
protease after viral budding.  
Reverse transcriptase and IN are generated from proteolytic cleavage of 
the Gag/Pol precursor polyprotein. RT is responsible for transcribing the 
RNA template and IN acts as a catalyst in the integration of the dsDNA viral 
template into the cellular genomic DNA.  
The 4.2 kb SS mRNA, transcribed from the Env gene, is translated into a 
68 kDa precursor which is post-translationally modified by glycosylation and 
cleavage into two proteins named gp46-SU, localized at the surface of the 
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infected cells and virions and responsible for the binding to the GLUT-1 
receptor, and gp21-TM, a transmembrane protein that mediates membrane 
fusion and formation of the virological synapse. HTLV-1 SU is a 312 amino 
acid protein. The C-terminal half of SU is highly antigenic and is recognized 
by serum antibodies from approximately 95% of HTLV-1 infected 
individuals. Early studies using site directed mutagenesis demonstrated 
functional domains within SU involved in intracellular maturation, syncytium 
formation, and the association between SU and TM Subsequent 
development of a cell transmission assay allowed for separation of fusion 
events from infectivity events.  
The HTLV-1 TM contains YSLI amino acid sequences, known to interact 
with cellular adaptor protein complexes, and a PDZ-binding motif (ESSL) at 
the C terminus of Env. Alterations of the YSLI motif increased Env 
expression on the cell surface and increased cell fusion activity, whereas 
mutations of the ESSL motif reduce Env expression in cells. HTLV-1 SU 
and TM form as heterodimers at the surface of virions and are responsible 
for initiating binding, fusion with target cell and entry.  
The mechanism of action that facilitates cell-to-cell transmission of the 
HTLV-1 is not resolved, but recently several groups have reported data on 
three main cellular receptors: glucose transporter (GLUT-1), heparin sulfate 
proteoglycans and neuropilin-1. Previous studies have shown GLUT-1 to 
be involved in envelope mediated cell-to-cell fusion. Heparin sulfate 
proteoglycan binds virus particles on cell surfaces and facilitates entry. In 
addition to being the main receptor, removal of heparin sulfate proteoglycan 
from primary lymphocytes significantly reduced binding of SU. Neuropilin-1 
is part of the immunological synapse and is a binding partner of Env. 
Ectopic expression of neuropilin-1 significantly increased HTLV-1 Env-
dependent syncytium formation. Further studies will be required to identify 
specific envelope motifs that both alter receptor binding and influence viral 
transmission and spread in vivo. 
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1.4.2 Expression of proteins coded in the pX region 
The pX region of the HTLV-1 genome contains at least four different 
partially overlapping open reading frames that code for non structural 
proteins of HTLV-1. As shown in Figure 2, expression of the different pX 
region genes is accessed through alternative splicing and polycistronic 
translation. All these mRNAs contain exon 1, which is non-coding. Singly 
spliced mRNAs contain exon 1 and different 3' exons, and code for the 
accessory proteins p13 (translated from a start codon located in the ORF II) 
and p12 (translated from a start codon in the ORF I) and for the 
accessory/regulatory protein p21rex (translated from a start codon located 
in the ORF III) [71; 76]. 
Two doubly spliced mRNAs contain exons 1 and 2, and different 3' exons. 
Exon 2 contains 2 start codons (AUGs). The regulatory proteins Rex and 
Tax are transcripted from a bicistronic mRNA. Rex initiates at the first AUG 
in exon 2 and continues in the ORF III in exon 3, while Tax initiates at the 
second AUG and continues in the ORF IV in exon 3. The 
accessory/regulatory protein p30, which is translated from the second start 
codon of exon 2 and continuing in frame with the x-II ORF in exon B 
[82;83]. Tax and Rex are required for viral replication.  
Tax is a potent transcriptional transactivator of viral gene expression. Tax 
also regulates the expression of several cellular genes, including those 
involved in cell proliferation, cell cycle progression, apoptosis, and DNA 
damage responses.  
Rex is a post-transcriptional regulator that facilitates nuclear export of 
unspliced and singly spliced viral mRNA. In addition, Rex inhibits splicing 
and transport of doubly spliced mRNA [77]. In contrast to Tax and Rex, Orf-
I and Orf-II are dispensable for viral replication in vitro but are important for 
viral persistence in vivo [78]. Early work demonstrated that in the rabbit 
model, Orf-I was required for viral infectivity while Orf-II was required to 
maintain high viral load [79; 80]. Further work in the rabbit model showed 
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reversion of HTLV-1 clones lacking p30 to the wildtype p30-expressing 
virus, suggesting the importance of p30 to HTLV-1 viral persistence [81]. 
However, in these early studies the HTLV-1 clones that were used 
contained a frameshift that affected HBZ, making it unclear as to whether 
these effects were due to the loss of hbz or Orf-I and Orf-II-encoded 
proteins. In a more recent study, the ablation of p12/p8, p30, or HBZ 
impaired the establishment of persistent infection in the macaque model 
[82]. Nevertheless, ablation of these proteins did not affect viral replication 
in the rabbit model [82]. The orf-I and orf-II-encoded proteins are able to 
modulate a diverse range of viral and cellular mechanisms including 
transcriptional regulation, mitochondrial function, cell cycle progression, 
host cell activation and proliferation, apoptosis, virus infectivity and 
transmission, and host immune responses. Though these proteins are not 
essential for virus replication in vitro, p8, 12, p13, and p30 have an 
important role in the establishment and maintenance of HTLV-1 infection in 
vivo. 
1.4.3 Expression of proteins coded by the negative strand of HTLV-1 
The negative strand of the HTLV-1 genome contains one ORF located in 
the pX region (antisense orientation) which generates at least 2 different 
transcripts, one spliced (hbz sp1) and the other unspliced (hbz us) [83; 84]. 
These transcripts code for 2 isoforms of HBZ protein that differ by 7 amino 
acids at the N-terminus due to the presence of the first exon only in the 
former transcript. Hbz sp1 has multiple transcriptional initiation sites in the 
U5 and R regions of the 3' LTR, whereas the hbz us transcript initiates 
within the tax gene. Both hbz sp1 and hbz us have TATA-less promoters 
[85]. 
1.5  Functions of the pX region proteins 
1.5.1 Tax 
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The HTLV-1 proto-oncogene Tax, a potent transcriptional activator of 
cellular and viral genes, is thought to play a pivotal role in the transforming 
properties of the virus by deregulating intracellular signaling pathways. Tax 
is a 40-kDa protein mainly localized in the nucleus translated from a 
doubly-spliced mRNA from the ORF IV [ 86 ; 87 ]. Tax is able to 
transcriptionally activate the expression of cellular genes involved in growth 
and proliferation [88] and to repress the expression of tumor suppressor 
genes [89]. Tax is responsible for initiating viral transactivation from the 
LTR of the provirus by binding the GC-rich regions of the TRE-1, within the 
U3 region of the LTR [90; 91; 92; 93]. From the TRE-1, Tax can stabilize 
the CREB/ATF (activator of transcriptional factors) dimers, which are part of 
the transcriptional machinery needed for viral gene expression [94]. Tax 
also can recruit and bind CBP/p300 to the TRE-1. Phosphorylation of 
CREB by PKA leads to recruitment of CBP/p300 in normal cells; however in 
HTLV-1 infected T-cells Tax can bypass PKA-mediated phosphorylation of 
CREB. The ability of Tax to recruit and stabilize CREB-CBP/p300 and other 
factors like P/CAF (CBP/p300 associated factor) allows for efficient 
transcription of the provirus [95].  
Tax can also bind TRE-2 in the LTR, which is located central and proximal 
to TRE-1. Tax recruits transcriptional co-activators like P/CAF and p300 
(via KIX domain), Ets family transcription factors (Ets-1, -2, Elf-1, Tif-1) and 
c-Myc transcription factors to the TRE-2 region [96]. Tax can also bind the 
basic region of cellular basic leucine zipper transcription factors (bZIP), 
which aid in DNA binding. The presence of TRE-1 and -2 allows for Tax to 
mediate a number of processes and facilitate viral transcription bypassing 
cellular signals.  
Tax dysregulates multiple cellular transcriptional signaling pathways 
including nuclear factor kappa B (NF-kB), cyclic AMP response element-
binding protein (CREB), serum responsive factor (SRF) and activator 
protein 1 (AP-1) [97]. These signaling pathways are responsible for the 
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expression of multiple pro-inflammatory and anti-inflammatory cytokines. 
Tax influences also the expression of several transcription factors like c-
Myc, c-Fos, c-Sis, Erg-1, c-Rel, and Lck and apoptosis and DNA repair 
genes like Bcl-XL, Bax and PCNA (proliferating cell nuclear antigen) [98].  
The transforming ability of Tax is most likely attributable to its influence 
over the expression of these important cellular genes. These pleiotropic 
properties of Tax confer to this protein a pivotal role in the viral 
pathogenicity and allow this viral protein to promote 
immortalization/transformation of infected cell, causing the onset of the 
HTLV-1-associated diseases [89; 97; 99 ]. Indeed, Tax activity is also 
associated with production of reactive oxygen intermediates (ROS), 
chromosomal instability and DNA damage. Changes in the intracellular 
redox status induced by Tax promote DNA damage. Tax-mediated DNA 
damage is believed to be essential in initiating the transformation process 
by subjecting infected T cells to genetic changes that eventually promote 
the neoplastic state. Apoptosis and immune surveillance would then exert 
the necessary selection pressure for eliminating the majority of virally 
infected cells, while escape variants acquiring a mutated phenotype would 
constitute a subpopulation of genetically altered cells prone to neoplasia. 
Thus, the cooperation of Tax with other viral proteins determines the fate 
and progression of HTLV-1-infected cells through DNA damage, apoptosis, 
survival and transformation (Figure 5). 
In contrast to other tumor viruses, which generally require continuous 
expression of viral oncoproteins to sustain transformation, tax gene 
transcripts were detected in only 34% of fresh ATLs [100], suggesting that 
Tax may be needed to initiate the transformation process, but may not be 
necessary for maintenance of the transformed phenotype. Interestingly, the 
HBZ antisense gene, transcribed from the 3′-LTR appears to be the only 
gene that is constitutively expressed in HTLV-1-infected and ATL cells 
[101]. Tax expression is typically low or undetectable, whereas HBZ gene 
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expression is maintained, suggesting that Tax and HBZ may cooperate in 
the process of leukemogenesis. Tax may initiate the transformation process 
inducing genetic instability, and HBZ expression may support survival of the 
infected cells. 
 
Figure 5. Pleiotropic functions of HTLV-1 Tax contribute to cellular 
transformation (Kendle Pryor and Susan J. Marriott, 2008). 
 
While the role of Tax in cell gene expression, proliferation, and 
transformation have been extensively studied, the role of Tax in viral 
transmission is less clear. Presumably, HTLV-1 would not be able to 
accomplish viral replication and spread without Tax function, but specific 
Tax determinants in viral transmission and spread are difficult to study. 
Infectious clones of the virus that have Tax mutations would fail to enhance 
needed viral gene expression during early stages of cell-to-cell 
transmission. Interestingly, prostaglandins enhance viral expression via the 
HTLV-1 LTR through the protein kinase A signaling and Tax transactivates 
a promoter for cyclooxygenase 2, a prostaglandin synthetase, and induces 
PGE2 expression in peripheral and cord blood mononuclear cells [102]. 
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This reciprocal interaction has been postulated to promote viral 
transmission in vivo.  
Several studies showed Tax involvement in promoting cell adhesion and 
thereby cell-to-cell transmission. Significant correlation exists in cell lines 
comparing expression of HTLV-1 Tax and CCL22 suggesting an active role 
of Tax in selective CD4+ T-cell viral transmission [103]. This conclusion is 
supported by transient Tax expression in an HTLV-1-negative T-cell line 
that induced CCL22 promoting CCR4 redistributed to cell contact points 
during in vitro transmission, and chemotaxis assays. Thus, HTLV-1-infected 
T-cells may selectively attract CCR4+CD4+ T-cells [103]. Similarly, Tax 
induced enhancement of ICAM-1 on the surface of T-cells has been shown 
to facilitate the formation of viral synapses and therefore may contribute to 
T-cell tropism and viral transmission [104].  
The detailed mechanisms of how specific Tax induced alterations of the 
host influence viral transmission and spread wait specific testing of tax 
mutations in context to full length and infectious viral clones.  
1.5.2 Rex 
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Rex is a 27 kDa nuclear/nucleolar phosphoprotein encoded by ORF III and 
it is expressed from a dicistronic doubly-spliced mRNA which contains exon 
1, 2 and 3, starting from the first start codon of exon 2 [105; 106]. Rex 
contains multiple functional domains including a RNA binding domain 
(RBS), nuclear localization sequence (NLS), a multimerization domain; and 
an activation domain, which includes the nuclear export signal (NES) [107]. 
Several studies indicate that Rex localization to its correct subcellular 
compartment is critical for its proper function [108]. Unlike Tax, Rex is able 
to shuttle between the nucleus and the cytoplasm [109 ], allowing the 
nucleo-cytoplasmic export of unspliced incompletely spliced and singly 
spliced mRNAs (Gag, Env, Pol) into the cytoplasm viral RNA, controlling in 
this way viral gene expression at the post-transcriptional level.  
The formation of Rex multimers on the RxRE is critical for the nuclear 
export of viral mRNA since mutations of Rex that failed to form multimers 
act as dominant negative mutants. In addition to functioning as a Rex 
exporter, CRM1 serves as an inducing factor for Rex multimerization on 
viral mRNA by aiding in complex formation. Residues 411 and 414 of 
CRM1 are critical for Rex multimerization, a region distinct from the one 
involved in the export of Rex. Mutations in the multimerization domains 
render Rex non-functional. The activation domain (AD) of Rex was 
originally identified as the minimal region that could functionally replace the 
HIV Rev activation domain in cis [110]. Subsequent studies showed that 
the sequence responsible for nuclear export of Rex, NES, is in fact its 
minimal effector domain. The NES in Rex is a leucine rich motif involved in 
protein-protein interactions that are critical for its function [111]. In addition 
to containing a unique Rex response element (RxRE) in the U3/R 3’ LTR, 
these mRNAs have cis-acting repressive sequences (CRS) that retain and 
stabilize the unspliced mRNA in the nucleus to ensure the availability of 
sufficient amount of Rex substrate [112; 113]. 
 25 
Figure 6 summarizes the Rex-mediated nucleocytoplasmic export of 
incompletely spliced viral mRNAs. After Rex-RxRE binding and Rex 
multimerization, CRM1 is recruited into the complex. CRM1 uses 
guanosine diphosphate/guanosinetriphosphate (GDP/GTP) guanine 
nucleotide exchange of the GTPase Ran to function. CRM1 binds to 
RanGTP, along with the Rex-mRNA complex, and translocates this 
complex across the nuclear pore by interacting with phenylalanine-glycine 
rich nucleoporins. In the cytoplasm RanGTP is then converted to RanGDP 
and is released from the Rex-mRNA complex. The regulator of 
chromosome condensation 1 (RCC1) catalyzes the conversion of GTP to 
GDP. Other proteins affecting Rex function include Ran Binding Protein 3 
(RanBP3), a scaffold protein that stabilizes the RanGTP-CRM1-Rex-mRNA 
complex in the nucleus, and SRC- associated in mitosis 68 (Sam 68), 
which is able to increment tRex-mRNA binding in a CRM1-independent 
fashion (Figure 6).  
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Figure 6. Rex-mediated nucleocytoplasmic export of viral mRNAs. Rex 
binding to the RxRE sequence in the viral mRNA after transcription (a). Rex 
multimerization (b) and viral mRNA/Rex/CRM1/RanGTP complex formation 
(c). Complex translocation from the nucleus to the cytoplasm is mediated 
by the interactions with phenylalanine-glycine rich nucleoporins (d). 
Conversion of RanGTP to RanGDP in the cytoplasm with subsequent 
complex dissociation and viral mRNA release (e). The other components of 
the complex return into nucleus to start another cycle (Younis and Green, 
2005). 
Rex, like HIV-1 Rev, appears to utilize the CRM1/exportin pathway [114; 
115]. There are two suggested models for the mechanism by which Rex 
induces cytoplasmic expression of unspliced mRNA. The first model 
proposes that Rex actively transports the unspliced mRNA to the cytoplasm 
where it is translated. Here, Rex would directly bind to the RxRE on the 
mRNA, override the nuclear retention signals, and carry this mRNA cargo 
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through the nuclear pore to the cytoplasm. The specific binding of Rex to its 
RxRE is a critical step in its transactivation of mRNA export by allowing the 
mRNA to overcome nuclear retention due to the inhibitory CRS [116]. The 
second model suggests that Rex actively inhibits splicing of mRNA by 
stripping it of splicing factors [117]. Once the mRNA is free of splicing 
factors the cellular machinery would recognize it as a processed mRNA 
and export it efficiently to the cytoplasm. The essential role of Rex for viral 
infectivity has been confirmed using molecular clones with selectively 
mutations in the rabbit model [118].  
A Rex-deficient HTLV-1 full length viral clone was used to provide the first 
direct evidence that functional Rex expression is not required for in vitro 
immortalization by HTLV-1, but was critical for optimal viral transmission in 
vivo [114]. These results suggest that defects in the ability of Rex to 
promote unspliced and single spliced RNA to traffic are important for 
optimal viral spread.  
1.5.3 p21 Rex 
p21 Rex is a protein coded by the ORF III located in pX region and it is 
expressed from a singly-spliced mRNA which contains exon 1 and 3. p21 
Rex is produced in HTLV-1 infected cells from alternatively spliced mRNAs 
and it is a truncated isoform of Rex lacking the N-terminal arginine-rich 
domain of the full-length protein (NLS, nuclear localizing sequence) and 
when expressed in cells inhibit RNA shuttling [119]. It was hypothesized 
that it might act as a repressor of full-length Rex, thereby inhibiting the 
expression of transcripts coding for structural proteins, enzymes and 
accessory proteins [120; 121] and playing a role as a latency-inducing 
factor in the HTLV-1 life cycle. 
1.5.4 p12 and p8 
HTLV-1 Orf-I encodes the 99 amino acid p12 protein which can be 
proteolytically cleaved at the amino terminus to generate the p8 protein 
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(Figure 3). Computational analysis of the amino acid sequence of p12 
predict the existence of a non-canonical endoplasmic reticulum retention 
signal, two putative leucine zipper (LZ) motifs which form α helices in the 
protein, two transmembrane domains, a calcineurin-binding motif, four 
putative proline-rich (PXXP) Src homology 3 (SH3)-binding domains 
responsible for binding cellular signaling proteins, and a putative adaptin 
motif  [122; 123].  
These structural features may contribute to protein localization, 
homodimerization, and protein-protein interactions. The p12 protein 
undergoes complex post-translational modifications through proteolytic 
cleavage. The first cleavage occurs between amino acid positions 9nd 10 
and is followed by a second cleavage between amino acids 29 and 30 
[122]. The first proteolytic cleavage removes the ER retention signal at the 
amino terminus of p12, while the second cleavage generates the p8 protein 
[122]. The p12 protein localizes to cellular endomembranes, particularly 
within the ER and Golgi apparatus, while p8 traffics to lipid rafts at the cell 
surface and is recruited to the immunological synapse upon T-cell receptor 
(TCR) ligation [122; 124; 125]. 
The singly spliced mRNA encoding p12/p8 has been detected in vitro and 
in ex vivo HTLV-1-infected T-cells and macrophages [ 126 ]. The p12 
recombinant protein is recognized in serum from humans infected with 
HTLV-1 and rabbits experimentally infected with HTLV-1 [127]. In addition, 
a cytotoxic T-lymphocyte (CTL) response to Orf-I products can be detected 
in HTLV-1-infected individuals [128]. 
Two natural variants of the p12 protein have been identified; one variant 
carries a lysine residue at position 88 and is commonly found in HTLV-1 
strains from TSP/HAM patients while the second variant carries an arginine 
residue at position 88 and is found in HTLV-1 strains from all ATL patients 
and healthy carriers studied. One of the most important domains of p8/p12 
is the conserved PSLP(I/L)T motif that is homologous to the calcineurin 
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binding motif present in Nuclear Factor of Activated T-cells (NFAT) [129]. 
This sequence has the capacity for calcineurin binding in the cell. 
Calcineurin and NFAT represent a few of the many Ca2+ signaling proteins, 
transcription factors, and ER/cis-Golgi associated proteins in the cytoplasm 
that p12 interacts with to influence gene expression infected T lymphocytes 
(Figure 7(2)).  
In addition to calcineurin and NFAT, calreticulin and calnexin bind p12 and 
mediate Ca2+ regulated pathways in the cell. These ER associated proteins 
are involved in regulating Ca2+ storage and signaling, respectively. 
Calreticulin is a chaperone protein responsible for retaining the MHC class I 
molecule folded in the ER along its maturation pathway. Calnexin assists in 
proper protein folding of glycoproteins that enter the secretory pathway. 
The modulation of NFAT activation and thus T-cell signaling is 
accomplished through interactions between Ras/MAP kinase by p12. When 
stimulated by phorbol ester and PMA, p12 can activate NFAT [130]. p12 
accomplishes this through releasing intracellular Ca2+ from ER storage and 
by increasing Ca2+ entry into the cell (Figure 7(1)) [131].  
HTLV-1 p12 has numerous effects on cell signaling when expressed 
exogenously. It can affect T-cell signaling or bind IL-2R β and γ subunits 
[132]. IL-2 expression is increased via NFAT activation in a Ca2+ dependent 
manner in Jurkat and primary T lymphocytes. In turn, this leads to a 
reduced dependency on IL-2 for T-cell activation in the presence of p12 
[133]. In addition to Ca2+ signaling related proteins, p12 can also bind 
vacuolar H+-ATPase and immature peptides of MHC class I, which leads to 
their proteosomal degradation [134;135]. In the ER, p12 binds to newly 
synthesized MHC-I heavy chains and prevents them from associating with 
the β2-microglobulin, a component of the mature MHC-I complex (Figure 
7(4)). Since improperly assembled proteins are removed from the ER for 
degradation, the p12-mediated inhibition of MHC-I heavy chain association 
with the β2-microglobulin leads to its degradation by the proteasome and 
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results in decreased MHC-I cell surface expression. By decreasing antigen 
presentation through degradation of the MHC-I, p12 may diminish 
presentation of viral peptides and decrease recognition by cytotoxic T-
lymphocytes [136]. Furthermore we know that NK cells recognize and 
destroy cells that express low levels of MHC-I at the cell surface. ORF-I 
decreases MHC-I expression to inhibit presentation of viral proteins to 
cytotoxic T-lymphocytes, which could make HTLV-1-infected cells 
susceptible to NK cell cytotoxicity [137]. In contrast, HTLV-1-infected T-
cells are resistant to NK cell-mediated killing [137]. Early data 
demonstrated that several ATL cells lines had altered expression of 
intercellular cell adhesion molecule 1 (ICAM-1), a glycoprotein that 
facilitates the interaction between NK cells and T-cells [138]. Furthermore, 
the majority of HTLV-1-infected primary CD4+ T-cells do not express 
ligands for the NK cell activating receptors, natural cytotoxicity receptors, 
and NKG2D [138]. 
IL-2 stimulation and p12 expression significantly increased the rate of 
syncytium formation, suggesting a novel role for IL-2 signaling and Jak 
activation in HTLV-1 virus transmission [139]. 
HTLV-1 p12 can be proteolytically cleaved to create a smaller protein, p8. 
This protein apparently serves a different role and acts to increase T-cell 
contact through LFA-1 clustering thereby enhancing the cellular contacts 
among T-cells to enhance viral transmission, while anergizing T-cell 
signaling (Figure 6(5)) [140]. The ability of p8 to decrease T-cell activation 
is likely mediated through inhibiting proximal T-cell receptor signaling at the 
immunological synapse where it decreases phosphorylation of key 
signaling proteins in a LAT-dependent mechanism (Figure 7(3)) [140].  
The ability of p12 to induce LFA clustering on infected T lymphocytes was 
previously demonstrated and hypothesized to increase the efficiency of 
cell-to-cell spread of the virus [141]. The processing of p12 into p8 may 
account for the influence of the ORF1 encoded proteins on LFA-1 
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clustering on the cell surface and the formation of cellular conduits [140]. 
Equally as plausible is the ability of p12 to induce calcium-mediated LFA-1 
clustering on the surface of T-cells, a known mechanism of LFA-1 
functional activation [142]. 
The transmembrane domains of ORF-I appear to be dispensable for 
binding to the V-ATPase, while conservation of the proline-rich domains 
between amino acids 36 and 48 contributes to the strength of this 
interaction [122]. The 16 kDa protein is a membrane component of the V-
ATPase, which is also found in clathrin coated vesicles, lysosomes, 
endosomes, Golgi vesicles, endoplasmic reticulum, and synaptic vesicles. 
This proton pump is responsible for the acidification of these intracellular 
vesicles [143]. The atypical function of the proton pump through binding of 
viral proteins such as HTLV-1 p12 may interfere in functions like the 
dissociation of receptor-ligand complexes and trafficking within the 
endosomal/lysosomal compartment. In addition, the acidification is 
essential for the formation of endosome carrier vesicles, which are 
intermediates between early and late endosomes [144]. HTLV-1 is known 
to infect dendritic cells and the acidification of lysosomes could play an 
important role in virus entry [145]. Indeed, the ablation of ORF-I expression 
impairs HTLV-1 replication in dendritic cells [7]. 
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Figure 7: Functions of p12 and p8. In the ER, p12 is proteolytically cleaved 
at the amino terminus to generate p8, which traffics to the cell surface 
through the secretory pathway. (1) In the ER, p12 mediates Ca2+ release, 
which enables (2) either calcineurin binding of NFAT and subsequent 
dephosphorylation, nuclear translocation, and upregulation of the IL-2 
gene, or p12 binding to calcineurin and inhibition of NFAT activation. (3) 
Upon trafficking through the secretory pathway, p8 localizes at the 
immunological synapse where it interacts with LAT and inhibits proximal 
TCR signaling. (4) In the ER, p12 binds the immature heavy chains of the 
MHC-I and prevents their interactions with the β2-microglobulin, leading 
MHC-I degradation by the proteasome. (5) At the cell surface, p8 increases 
the clustering of LFA-1 and the formation of intracellular conduits and 
facilitates viral transmission to target cells. (Edwards et al., 2011) 
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The first evidence that pX ORF-I was important for viral transmission was 
demonstrated in the rabbit model using a splice acceptor site mutant of the 
ACH infectious molecular clone [146]. Ablation of the acceptor splice site 
through the deletion of four nucleotides was associated with a reduction of 
viral infectivity in vivo [146] and in vitro in non-stimulated T-cells. The 
deletion of this p12 acceptor splice site would also introduce a frame shift in 
the HBZ antisense ORF, resulting in the deletion of the last 24 amino acids 
of HBZ [147]. 
However the replication capacity of subsequent specific HBZ mutants in 
context of molecular clones did not result in complete reduction of infectivity 
as observed in ORF1 splice mutants. Thus, the rabbit model was able to 
detect selected HBZ mutations and demonstrated that these were different 
in viral spread compared to ORF-I mutants. A recent study tested a variety 
of HTLV-1 mutant molecular clones for their ability to replicate in dendritic 
cells and in vivo in rabbits and macaques [82]. In this study, mutations to 
ablate p12, p30, and HBZ were introduced in the ClaI/SalI cassette from 
the HTLV-1 molecular clone pBST that encompasses the orf-I and the orf-
II. Rabbits inoculated intravenously with these mutant clones had reduced 
viral loads at 16 weeks post inoculation before recovering to wild type 
control level. Dendritic cell cultures from macaques infected with these 
mutant clones had reduced viral replication parameters suggesting the 
importance of this cell type in early viral transmission [82]. Small groups of 
macaques inoculated with these same mutant molecular clones also 
exhibited limited viral expression [82] confirming the importance of p12/p8 
and p30 expression for viral transmission. 
1.5.5 p13 
Differential splicing of mRNA from HTLV-1 orf-II results in production of the 
p13 protein  [ 148 ; 149 ; 150 ]. p13 is translated from singly spliced 
monocistronic mRNA to form a highly basic 87 amino acid protein that 
corresponds to the carboxyl terminus of p30 (Figure 3) [148]. The p13 
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protein has been predicted to contain a short hydrophobic leader sequence, 
an amino terminus mitochondrial targeting signal (MTS) which allows the 
viral protein to target the mitochondria and is a predicted α-helix that is 
arginine rich and amphiphatic [151; 152], a transmembrane domain, a 
flexible hinge region and a carboxyl terminus β-sheet hairpin structure [153; 
152]. The carboxyl terminus region contains multiple PXXP motifs that may 
mediate Src homology 3 (SH3) ligand binding. In addition, the carboxyl 
terminus region contains a cryptic nuclear localization sequence (NLS) 
[ 154 ]. The viral protein is predominantly localized within the inner 
membrane of mitochondria of transfected cells [151]. However, when 
expressed at high levels, p13 is able to localize within the nucleus and, 
when coexpressed with Tax, is directed to nuclear speckles [ 155 ]. 
Localization of the p13 protein within mitochondria and the nucleus 
suggests that this protein may modulate effects on apoptosis and 
transcriptional regulation (Figure 8). The incorporation of p13 into the inner 
mitochondrial membrane causes morphological changes such as swelling 
and a loss of inner membrane potential (∆ψ) changing K+ permeability of 
these organelles. The effects of p13 on K+ permeability are dose-dependent 
[152]. p13-induced K+ influx and mitochondrial membrane depolarization 
stimulates electron transport and mitochondrial respiration, which increases 
O2 consumption and change energy production, redox status and induce 
apoptosis in cells [152]. Modulation of respiratory chain activity by p13 is 
accompanied by increased mitochondrial reactive oxygen species (ROS) 
production. Changes in mitochondrial ∆ψ also regulate intracellular Ca2+ 
homeostasis (Figure 8(2)). A p13 peptide was found to induce rapid efflux 
of Ca2+ from preloaded mitochondria. Though p13 reduces mitochondrial 
Ca2+ uptake, it does not significantly affect overall change in cytosolic Ca2+ 
concentration, suggesting that p13-mediated mitochondrial depolarization 
may alter Ca2+ concentration only locally [156]. 
Ectopic expression of p13 affects structure and disrupts the inner 
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membrane potential of mitochondria [152]. The ectopic expression of p13 
causes HeLa and Jurkat T-cells to be sensitive to caspase-dependent, 
ceramide- and FasL-induced apoptosis. A farnesyl transferase inhibitor that 
prevents post-translational modification of Ras blocks this suppressive 
effect of p13 [157].  
Interestingly, primary T-cells that express p13 are activated, while causing 
transformed cells to be sensitive to reactive oxygen species. Studies of a 
p13-knockout virus showed that although the protein is dispensable for viral 
replication in cultered cells, it is required for establishing a persistent 
infection in a rabbit experimental model [157]. 
Collectively these studies indicated that p13 has the ability to modulate cell 
survival via Ras-mediated cell signaling and has an essential role early 
virus transmission and in virus persistence. p13 interacts with farnesyl 
pyrophosphate synthase (FPPS), which is involved with synthesis of FPP 
substrate and is required for prenylation of Ras and subsequent activation 
of Ras [158]. In cells expressing Tax, p13 becomes ubiquitinated and is 
partially localized within the nucleus (Figure 8(4)) [159]. Interestingly, Tax 
mediates ubiquitination of p13 though this protein contains no lysine 
residues. Instead, p13 is likely ubiquitinated on serine and threonine 
residues and this modification increases the stability of the protein. Within 
the nucleus, ubiquitinated p13 associates with Tax to inhibit its binding to 
the CBP/p300 transcriptional coactivator [159]. A decrease in Tax-
CBP/p300 complex formation results in decreased Tax-mediated viral gene 
transcription [159]. Thus, intracellular localization of p13 may be an 
additional regulatory switch between viral replication and latency. 
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Figure 8. Functions of p13. In mitochondria, p13 mediates (1) K+ influx, 
inner mitochondrial membrane potential, and electron transport chain 
activity to affect (2) Ca2+ signaling and (3) ROS production. (4) In the 
presence of Tax, p13 is ubiquitinated and translocates to the nucleus. In 
the nucleus, p13 inhibits Tax-CBP/p300 complex formation to decrease 
transcription of cellular and viral genes. (Edwards et al., 2011) 
1.5.6 p30 
In 1992, two groups independently reported a new doubly spliced mRNA 
which potentially encodes for two viral proteins. The first one shares the 
Env/Tax AUG and encodes for the nuclear/nucleolar p30. The second one 
is shorter and encodes for p13. Only indirect evidence of p30 protein 
expression in patients infected with HTLV-1 exists. However, this is also 
true for most other viral proteins, including Tax and Rex, and this possibly 
reflects the latent state of the virus in vivo. p30-encoded mRNAs can be 
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readily detected in HTLV-1-infected cell lines in vitro and in some freshly 
isolated samples from HTLV-1-infected subjects, and ATL and HAM/TSP 
patients. Antibodies directed to p30 and cytotoxic T cells that recognize 
peptides from p30 have been found in HAM/TSP patients and HTLV-1 
carriers [160]. p30 is dispensable for T-cell immortalization in vitro but is 
required for efficient viral propagation in vivo [161]. 
The p30 protein is translated from doubly spliced monocistronic mRNA, 
containing exons 1, 2, and B, transcribed from HTLV-1 orf-II (Figure 3) 
[162; 163]. p30 is a highly basic protein with a net positive charge that 
contains three nuclear localization signals (NLS1, NLS2, and NLS3) and an 
arginine-rich nucleolar localization and/or retention (NoRS) domain [164]. 
p30 also contains a Rex-binding domain (RexBD), a p300-binding domain, 
and a DNA-binding domain [ 165 ] which repress LTR-mediated 
transcription. Notably, HTLV-1 p30 has low genetic variability and is similar 
to HTLV-2 p28, suggesting a conserved mechanism for negative 
modulation of virus replication [164; 166]. Live cell imaging technologies, 
indicated a high mobility of GFP-p30 in the nucleus. In contrast, a much 
slower kinetic was consistently detected in the nucleolus, suggesting that 
p30 is strongly retained in the nucleolus [164]. Specifically, p30 is located in 
a granular component of the nucleolus where ribosome subunits are 
assembled and de novo mRNA is produced. In fact, p30 was found to 
interact with the large ribosomal subunit L18a18. These interactions were 
functionally relevant and played a role in p30 nucleolar retention along with 
nascent mRNA. Several studies have shown that the ribosomal protein 
L18a interacts with eukaryotic initiation factor-3 and facilitates internal re-
initiation of translation, it is possible that p30 translocates from the nucleoli 
to the cytoplasm (Figure 9(1)) [165]. Similarly, p30 is specifically 
delocalized from the nucleoli to the nucleoplasm upon DNA damage to 
interfere with DNA repair processes [ 167 ]. In addition, p30 nucleolar 
retention signal mutants have similar functionality as wildtype p30, which 
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raises questions about the function of nucleolar localization. A recent 
hypothesis suggests that p30 retention within nucleoli may serve as a 
reservoir for when the protein is needed in the nucleus [167]. Interestingly, 
it has recently been shown that HBZ mRNA can regulate the production of 
p30, probably acting as an antisense RNA to silence its expression (Figure 
9(4)) [168]. Localization of p30 within the nucleus and nucleolus suggest 
that this protein may mediate critical cellular processes such as cell cycle 
progression, DNA repair, and mRNA export [ 169 ]. Intriguingly, recent 
studies have shown that in a macaque model, ablation of p30 within the 
HTLV-1 provirus severely affects infectivity and leads to reversion of the 
virus to the wild type genotype [82]. This observation has been confirmed in 
vitro by p30 knockout in HTLV-1-infected human primary and monocyte-
derived dendritic cells, in which infection is not sustained over time. In T-
cells, p30 is not required in vitro for efficient viral replication [82]. 
p30 has different functions: 
• inhibition of Nuclear Export of Tax/Rex mRNA 
• repression of the CRE Pathway 
• transcriptional and posttranscriptional Regulation of different 
pathways 
• control on cell cycle and DNA Repair 
• viral persistence in animal models 
In contrast to HTLV-1 Tax and Rex, which enhance viral replication, p30 
blocks the nuclear export of tax/rex mRNA to the cytoplasm, resulting in 
down-regulation of both positive regulators Tax and Rex, suppression of 
virus replication and latency to escape host immune surveillance and to 
favor propagation through cell division and clonal expansion of infected 
cells (Figure 9(5)) [170]. p30 can perform all these actions interacting with 
the p30 mRNA-responsive element (p30RE) of Tax/Rex mRNA and with 
Rex at the RexBD. Interestingly, p30RE spans the exon junction created 
after Env mRNA is spliced, hence p30 binds spliced Tax/Rex mRNA but not 
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the unspliced and singly spliced viral RNA.  
The interplay between Rex and p30 is a regulatory switch between viral 
replication and latency. p30 specifically forms complexes with Rex and p30-
Rex interactions are markedly increased by the presence of viral mRNAs. 
Rex binds with high affinity to the Rex-responsive element (RexRE) at the 
3' end of viral mRNA and, together with CRM1, shuttles unspliced gag/pol 
and singly spliced env transcripts to the cytoplasm (Figure 8(3)). Once 
bound to mRNA, Rex is no longer accessible to binding by p30 and is able 
to shuttle transcripts to the cytoplasm. However, viral mRNA-bound p30 
efficiently interacts with Rex, but tax/rex transcripts are still retained in the 
nucleus (Figure 9(5)) [171]. An excess of Rex, which displaces p30 from 
the p30RE, reverses nuclear retention of viral mRNA. A further spliced 
version of Tax/Rex has been found in HTLV-1 infected cells, p21rex. During 
splicing of p21rex, the p30RE is removed from Rex mRNA, which allows 
the transcript to escape p30-mediated nuclear retention.  
In addition to its post-transcriptional activity, p30 has been reported to have 
transcriptional activities both as activator or repressor. When fused to the 
Gal4 DNA-binding domain, p30 shows strong transcriptional activation. The 
ability of p30 to induce transcriptional activation in vitro is CBP/p300-
dependent [172].  
Additional studies showed that p30 repressed the cellular CREB-
responsive element-driven reporter gene activity in a dose-dependent 
manner. When expressed at low levels, p30 was shown to activate the 
HTLV-1 LTR reporter gene. However, at high levels, p30 repressed the 
LTR reporter activity [172]. Several other proteins bind CBP/p300, including 
members of the Jun-family, c-Myb, c-Fos, STAT1/2, NF-κB, p53, and 
TATA-binding protein (TBP) [82]. p30 disrupts CREB-Tax-p300 complex 
formation on the TRE (Tax-responsive element) of the viral LTR, resulting 
in repression of HTLV-1 transcription [173]. 
Therefore, the expression level of p30 may play an important role in its 
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function in the cell. Because p30 suppresses Tax production by retaining 
tax/rex mRNA in the nucleus, it affects CRE- and TRE-mediated 
transcriptional activation [88]. Interestingly, histone acetyltransferase (HAT) 
activity of p300 modulates p30-dependent transcriptional downregulation, 
whereas p30-dependent LTR repression is enhanced by deacetylation and 
inhibited by acetylation [173]. Taken together, these data suggest that p30 
might decrease transcription of the viral genome, thereby facilitating viral 
latency. 
Microarray gene expression analyses of human T-cells showed that HTLV-
1 p30 affects a number of cellular genes at the transcriptional level. p30 
represses many cellular genes, particularly adhesion molecules, such as 
integrins and cadherins, but increases the expression of certain target 
genes involved in T-cell activation and apoptosis [174]. Furthermore, p30 is 
able to retain some cellular transcripts within the nucleus, similarly to viral 
tax/rex mRNA. Included among these transcripts are MDM4, which is a 
regulator of p53, and HDAC3, which is a histone deacetylases involved in 
transcriptional repression.  
Moreover, p30 has been shown to interact with the cellular transcription 
factor PU.1 in human macrophages. PU.1, also known as Spi-1, is a 
transcriptional factor comprised in the ETS family. Its expression is cell-
specific and it has been found in macrophages, dendritic cells, B-cells and 
neutrophils. PU.1 plays a critical role in cell activation and differentiation. 
Interestingly, PU.1 can interact with a variety of factors, including IRF4, 
ICSBP/IRF8, JUN and NFkB, and promotes transcription of type 1 
interferons (IFNs) [23-30]. Therefore, PU.1 is involved in the signal 
transduction upon activation of different toll like receptors (TLRs) including 
signal transduction by Toll-like receptor-4 (TLR-4) [175]. The interaction of 
p30 and PU.1 leads to inhibition of the DNA binding and transcriptional 
activity of PU.1. This, together with the p30-mediated inhibition of GSK-3β, 
yields decreased expression of TLR-4 at the cell surface, resulting in 
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decreased secretion of pro-inflammatory cytokines, such as MCP-1, TNF-α 
and IL-8, and an increase of the anti-inflammatory cytokine IL-10 [175]. 
This finding is of interest because 80% of ATL patients have high levels of 
IL-10 in serum. Interference of TLR4 signaling by p30 and reduction of 
released amounts of pro-inflammatory cytokine IL-10 may impair the ability 
of dendritic cells to activate adaptive immunity in ATL patients and thereby 
explain the limited proliferation of virus-specific CTL reported in ATL 
patients. These data indicate a global effect of p30 on numerous genes in 
infected cells, suggesting that p30 is involved in more than just virus 
replication control. Until now, no consistent DNA response element has 
been reported, so the function of p30 in transcription of cellular genes 
remains to be determined [176]. 
Expression of p30 results also in the accumulation of T-cells in the G2 
phase of the cell cycle. p30 is able to enhance phosphorylation and 
activation of check point kinase 1 (Chk1). Chk1 is activated by ATM/ATR 
kinase following single strand DNA damage and results in a G2 arrest of 
the cell cycle [177]. p30 specifically binds to ataxia-telangiectasia mutated 
(ATM) and regulator of 20S proteasome activators γ (REGγ) in multiprotein 
high molecular weight complexes. By binding to ATM, p30 prolongs cell 
survival following DNA damage by inhibiting ATM autophosphorylation and 
subsequent activation of proteins involved in DNA repair, cell cycle check 
points, and apoptosis [178]. The effect of p30 interactions with REGγ 
remains to be determined. REGγ is localized in the nucleus where it 
interacts with and stabilizes p30, thereby altering p30 turnover. In addition, 
p30 is able to bind to and prevent complex formation of cyclin E and cyclin-
dependent kinase 2 (CDK2). Disruption of this complex prevents 
phosphorylation of retinoblastoma and subsequent E2F-mediated 
transcription, two key steps for G1/S transition [179]. By inhibiting cyclin E-
CDK2 complex formation, p30 delays entry of cells into the S phase of the 
cell cycle. The inhibition of cell cycle progression is consistent with the 
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observation that dendritic cells isolated from peripheral blood of ATL 
patients are unable to stimulate proliferation of CD4+ and CD8+ T-cells 
[180].  
p30 is also able to interact with multiple proteins involved in DNA repair 
processes. Upon DNA damage, p30 specifically delocalizes from the 
nucleolus to interact with and affect correct assembly of MRN complexes. 
MRN complexes are a key factor of DNA repair and contribute to 
homologous recombination (HR) during the S phase of the cell cycle. In 
contrast, during G1 or M phases, DNA damage is preferentially repaired by 
the nonconservative nonhomologous end joining (NEHJ) pathway. By 
interacting with these complexes, p30 activates a shift from conservative 
HR to the error-prone NEHJ pathway, thus favoring an accumulation of 
genomic alterations. Overall, these observations suggest that p30 could 
contribute to the accumulation of mutations that are characteristic of 
transformed HTLV-1-infected T-cells. 
HTLV-1 p30 exact function and relevance in vivo still remains elusive. It has 
been previously shown in vitro that the ablation of p30 expression does not 
affect viral infectivity of HTLV-1 in human primary cells and that p30 is 
dispensable for viral replication and immortalization of primary human T-
lymphocytes [181]. It should be noted that the in vitro infectivity of p30-
ablated HTLV-1 was not sustained over time in primary dendritic cell [82]. 
Other observations, such as the presence of antibodies to p30 during 
infection may provide evidence of the importance of p30 in vivo [182]. It 
was first shown that the ablation of p30 expression in vivo result is a 
dramatic decrease of HTLV-1 viral load in a rabbit model [183]. However, 
the mutation introduced to prematurely stop the translation of p30 affected 
hbz as well, whose ablation alone decreases viral replication [184]. Later 
studies have used different mutations to ablate p30 expression while 
preserving hbz [82]. Valeri et al showed that in the macaque model, but not 
in the rabbit model, the ablation of p30 expression within a biologically 
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active HTLV-1 molecular clone (p30-KO) or p12/p8 (p12-KO) severely 
affects its infectivity. When infection occurs in the case of p30-KO, it is 
associated with early reversion of the virus to the wildtype genotype, where 
in the case of p12-KO, neither infection non-genetic reversion is observed 
underscoring the importance of these viral genes [82]. Furthermore, the 
infectivity of p30-KO and p12-KO in human primary monocyte-derived 
dendritic cells (Mo-mDCs) is also severely impaired. In contrast, the lack of 
expression of p30 or p12/p8 in human B-cells [82] or primary human CD4+ 
T-cells (our unpublished data) does not affect viral replication in vitro.  
 
Figure 9. Functions of p30. (1) Alternatively double spliced mRNA is 
translated to form the Tax and Rex regulatory proteins. (2) Tax protein 
localizes to the nucleus to exert its function on the LTR as a positive 
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regulator of viral transcription. (3) Within the nucleus, Rex recognizes the 
Rex-responsive elements (RexRE) of viral mRNA and shuttles these 
transcripts to the cytoplasm while inhibiting splicing processes. However, 
some of the viral RNA is processed in the spliced env mRNA, the double 
spliced p30, (4) and the alternatively spliced tax/rex mRNA. p30 mRNA is 
subject to negative regulation by hbz mRNA. Once p30 protein is produced, 
it translocates to the nucleus and (5) interacts with p30-responsive 
elements (p30RE) created by the double splicing and therefore is present 
on tax/rex mRNA only. Moreover, p30 interacts with Rex to inhibit Rex-
mediated nuclear export of double spliced viral mRNA, including tax 
transcripts. By preventing Tax production, p30 decreases viral transcription. 
(Edwards et al., 2011) 
1.5.7 HBZ 
The presence of an anti-sense transcript of HTLV-1 was first detected by 
Northern blot in HTLV-1-infected cell lines [185]. However, the function and 
exact structure of this gene product remained unknown. In 2002, a viral 
protein that binds to CREB-2 was found by yeast two-hybrid screening, and 
named HTLV-1 bZIP factor (HBZ). HBZ was first found to inhibit viral gene 
transcription of the sense strand [186]. The negative strand of the HTLV-1 
genome contains one ORF located in the pX region (antisense orientation) 
(Figure 3) which generates at least 2 different transcripts, one spliced (hbz 
sp1) and the other unspliced (hbz us) [187; 188; 189]. The first exon of the 
HBZsp1 gene transcript is present in U3 and R regions of the 3′LTR. The 
difference between HBZ sp1 and HBZ us is the presence of the first exon in 
the former transcript so only 7 amino acids in the N- terminus. Hbz sp1 has 
multiple transcriptional initiation sites in the U5 and R regions of the 3' LTR, 
whereas the hbz us gene initiates within the tax gene. Both hbz sp1 and 
hbz us have TATA-less promoters [190]. It has been reported that the basal 
transcription factor Sp1 is critical for many TATA-less promoters [191; 192]. 
Since Sp1 is a well-known regulator of housekeeping genes, transcription 
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of the HBZ gene may be relatively constant. The TRE sequence in the 3' 
LTR also functions to enhance transcription of the hbz anti-sense 
transcripts. However, the enhancing activity for anti-sense transcription is 
relatively weak when compared with sense transcription. It is known that 
the HBZ gene transcript is better correlated with proviral load than the tax 
gene transcript [193], indicating that the HBZ gene is constantly expressed 
in HTLV-1 infected cells particularly in ATLL cases.  
Quantitative analyses of the HBZ gene transcripts showed that The HBZ 
SP1 protein is fourfold more abundant and has a longer half-life than HBZ 
US isoform [194], and the hbz sp1 mRNA is expressed at higher levels 
compared to the hbz us mRNA [195]. This observation correlates with the 
finding that the promoter activity of the HBZsp1 gene was much higher than 
that of the HBZ us gene.  
Relative expression level of the HBZ gene, adjusted by proviral load, was 
almost equivalent among HTLV-1 carriers, HAM/TSP patients, and ATL 
patients [196]. A previous study reported that HTLV-1 proviral load was 
correlated with the expression level of the tax gene [197]. However, the 
HBZ gene transcript was more closely correlated with proviral load than 
was the level of the tax gene transcripts [196]. Kinetic study of the HBZ sp1 
gene transcripts in rabbits shows that HBZ sp1 gene transcription was 
detected one week post-infection and increased and stabilized, while other 
viral genes were at or below the limit of detection [198]. This finding 
supports a correlation between HBZ sp1 gene expression, proviral load, 
and survival of HTLV-1 infected cells. HBZ gene expression is closely 
linked with disease severity of HAM/TSP, suggesting that the HBZ gene 
expression plays critical roles in proliferation of HTLV-1 infected cells and 
pathogenesis. 
The spliced transcript of HBZ is translated into a polypeptide of 206 amino 
acids, while the protein product of unspliced HBZ is a polypeptide of 209 
amino acids. The HBZ protein contains 3 domains: an N-terminal 
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transcriptional activation domain (AD), a central domain (CD) and a C-
terminal basic ZIP domain (bZIP). It localizes in the nucleus with a speckled 
pattern and contains three regions associated with its nuclear localization: 
two regions rich in basic amino acids and a DNA binding domain [199].  
HBZ is not necessary for viral replication or immortalization in vitro of T 
cells, although mutation of the HBZ gene resulted in decreased proliferation 
of infected cells in vivo [ 200 ], implicating HBZ in infectivity and viral 
persistence.  
HBZ interacts with a number of transcription factors, including CREB-2, 
p300/CBP, Jun family members, and NF-kB. Through interactions mediated 
by its bZIP domain, HBZ abolishes the ability of CREB-2 to bind to theTax 
responsive element (TxRE) in HTLV-1 LTR, resulting in the suppression of 
transcription from the 5' LTR by Tax (Figure 8) [201]. HBZ interacts with 
cellular coactivator CBP/p300 in its N-terminal region, leading to 
suppression of viral transcription by inhibiting the recruitment of CBP/p300 
to the HTLV-1 promoter [202].  
So far, there is no report that HBZ has the capacity to associate with DNA 
directly. It is apparent that HBZ exerts its suppressive effect on HTLV-1 
transcription mainly by interacting with cellular proteins on the HTLV-1 
promoter. HBZ's bZIP domain also mediates formation of heterodimers with 
several AP-1 transcriptional family members, such as c-Jun, JunB, and 
JunD, but not c-Fos and modulates their activity (Figure 10) [203; 204]. 
Binding of HBZ to JunB and c- Jun decreases their DNA binding capability 
by preventing their interaction with Fos, leading to repression of the AP-1 
complex. Additional AP-1 transcriptional repression is explained by HBZ 
inhibition of c-Jun by promoting the degradation of its protein product [205] 
(Figure 10) and sequestration of JunB by HBZ within nuclear bodies. In 
contrast to JunB and c- Jun, the interaction of HBZ with Jun-D, another 
member of AP-1 family, stimulates its transcriptional activity, and results in 
the activation of JunD-dependent cellular genes (such as Sp1) including 
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human telomerase reverse transcriptase (hTERT) (Figure 8) [204;206].  
NF-κB is activated in HTLV-1 infected cells and ATL cells. Activated NF-κB 
plays important roles in the proliferation of ATL cells and inhibition of 
apoptosis [ 207 ]. HBZ has been shown to inhibit the activation of the 
classical NF-kB pathway by two different mechanisms (Figure 9): by 
inhibiting the DNA binding of the NF-kB subunit p65 or by increasing the 
expression of PDLIM2, the E3 ubiquitin ligase of p65, leading to enhanced 
ubiquitination and degradation of p65 [208]. NF-κB suppressive activities 
are common among different viruses, suggesting that these suppressive 
activities are important for viral infection. A virus might escape from the 
host immune system by suppressing the classical NF-κB pathway.  
Suppressed expression of the HBZ gene by shRNA leads to decreased 
proliferation of ATL cell lines so HBZ expression is associated with 
proliferation of ATLL cells in vivo an d in vitro [209 ; 210 ]. Mutational 
analyses of the hbz gene showed that hbz mRNA, rather than HBZ protein, 
has a growth-promoting effect on T-cells [210]. The coding sequence of the 
HBZ gene was replaced with silent mutations, which could produce the 
same protein while the RNA structure was completely altered. This mutant 
did not have a growth-promoting activity. Only HBZ sp1 RNA, not HBZ us 
RNA, promotes proliferation of T-cells, indicating that the first exon of the 
HBZ sp1 transcript is critical for this activity [211]. Further details of how 
HBZ sp1 RNA promotes proliferation remain to be elucidated.  
An intriguing aspect of ATLL pathogenesis is represented by the fact that 
Tax expression is not detected in about 60% of leukemia cases despite its 
proven central role in leukemogenesis; i.e. it immortalizes T-lymphocytes in 
vitro and induces cancer in transgenic animals [212]. Three mechanisms 
for inactivating Tax expression have been described: 
• genetic changes (nonsense mutation, deletion, and insertion) of the 
tax gene [212];  
• deletion of the 5' LTR (which is a promoter/enhancer of viral gene 
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transcription of the plus strand) [213]; 
• CpG sites of the 5' LTR hypermethylation [214].  
These findings suggest that Tax expression is not necessary in the late 
steps of the leukemogenic process although its expression is required at an 
early stage of ATL or in the carrier state. One possible scenario is that 
since Tax is the major target of cytotoxic T-lymphocytes (CTL) in vivo, 
these mechanisms to disrupt or decrease Tax expression facilitate the 
escape of ATLL cells from host CTL. Interestingly, analyses of HTLV-1 
proviruses in ATLL cells revealed an intact hbz gene and lack of deletion or 
methylation of the 3' LTR [215], suggesting that hbz gene expression plays 
a critical role in the development of this disease. 
HBZ gene is responsible for leukemogenesis by HTLV-1. Further, HBZ 
might be a novel target for prevention of, and therapies for, HTLV-1-
associated diseases. 
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Figure 10. Functions of HBZ. HBZ protein interacts with c-Jun or CREB 
and suppresses viral transcription from the 5′LTR. HBZ mRNA promotes T-
cell proliferation. A transcription factor, SP1, plays a critical role in the HBZ 
gene transcription. (Masao Matsuoka, 2010). 
1.6 Type 1 Interferons and the Virus Host Relationship 
Viruses have adapted strategies to evade or even inhibit key elements of 
host immune responses. Because particular arms of the responses are 
susceptible to microbes escape mechanisms, the host has evolved several 
ways to activate a broad range of defense mechanisms to ensure effective 
protection. An example of these means could be type 1 IFNs that are 
important molecules for antiviral defense and immune regulation. The host 
has a variety of pathways to elicit the expression of the IFN-α/β cytokines. 
Cellular sensors fall into two functional classes that differ fundamentally 
with respect to localization, associated with either the cell membrane or the 
cytoplasm (Figure 11). An important biological consequence of this 
differential localization is the flexibility of the host in triggering type 1 IFN 
production, either in infected cells and/or before cells are exposed to viral 
products capable of blocking induction. There are two other types of 
interferon, which can be differentiated from type 1 based on the type of 
receptor through which they signal: IFN type 2 binds to IFNGR (IFNγ) and 
IFN type 3 which signal trough a receptor complex (IL10R2 and IFNLR1). 
These IFNs directly activate macrophages and natural killer cells. 
1.6.1 Extracytoplasmic pathways for pathogen sensing: Toll-like 
receptors 
Toll-like receptors (TLRs) are an essential arm of the innate immune 
response to bacteria, viruses and fungi and link recognition of distinct 
features of these microbes to the induction of pro-inflammatory signaling 
pathways. The Toll-like receptor (TLR) family is composed of membrane 
proteins with domains designed to sample the environment for pathogen-
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associated molecular patterns (PAMPs) [216]. Different TLR molecules 
recognize specific PAMPs: multiple microbial products can serve as 
ligands, including LPS (TLR4), lipopeptides (TLR2/1 and TLR2/6), flagellin 
(TLR5), and TLR3, TLR7, TLR8, and TLR9 appear to play important roles 
in identifying viral products. Particularly TLR9 recognize unmethylated CpG 
motifs in DNA, and TLR7 and 8 single-stranded RNA. In contrast, TLR3 
appears to represent a more general sensor of viral infection through 
detection of double-stranded RNA (dsRNA), a product of viral replication 
and transcription for both RNA and DNA viruses. Accordingly, TLR9 
becomes activated in response to infection with DNA viruses such as 
herpesviruses, and TLR7 and TLR8 respond to RNA viruses such as 
influenza viruses and HIV. TLRs can also be subdivided into two groups 
based on their localization within the cell. While TLR1, TLR2, TLR4, TLR5 
and TLR6 are localized at the cell surface, the nucleic acid-sensing TLRs, 
TLR3, TLR7, TLR8 and TLR9 are localized intracellularly within 
endolysosomes. This intracellular localization facilitates recognition of 
nucleic acids released from microbes degraded within endolysosomes.  
After recognition of pathogens, TLRs become activated and transmit 
signals through their cytoplasmic Toll/ interleukin-1 receptor (TIR) domains, 
resulting in the transcriptional induction of multiple genes involved in innate 
and adaptive immunity, including type 1 IFN.  
TLR3 induction of type 1 IFN is mediated through the TIR domain–
containing adaptor- inducing IFN-β (TRIF). TRIF mediates the activation of 
IkB kinase ε (IKKε) and tank binding kinase 1 (TBK1), which phosphorylate 
IFN regulatory factor 3 (IRF3), resulting in its dimerization and nuclear 
translocation where it promotes gene transcription. TRIF also mediates the 
activation of neural factor kB (NF-kB) and activating protein 1 (AP1) 
through the kinase complex IKK α/β/γ and the mitogen-activated protein 
kinase (MAPK) cascade, respectively [ 217 ]. These three transcription 
factors (IRF3, NF-kB, and AP1) coordinate the transcriptional regulation of 
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the IFN β gene. Induction of type 1 IFN by TLR7/8/9 is mediated by the 
adaptor molecule myeloid differentiation primary response protein 88 
(MyD88), which associates with the TIR domain of the TLRs, the 
interleukin-1 receptor–associated kinases IRAK1 and IRAK4, and the tumor 
necrosis factor receptor–associated factor 6 (TRAF6). This results in 
downstream activation of IRF7, and of the IKK α/β/γ and the MAPK 
cascades, leading to NF-kB and AP-1 activation [217]. Both TLR3 and 
TLR7 and 8 are able also to activate via IRFs a transcription factor called 
PU.1, which is responsible of the transcription of different interferon 
stimulated genes (ISGs). 
1.6.2 IFN-Mediated Effects On Defense 
As secreted factors, the type 1 IFNs regulate a range of immune responses 
through the type 1 IFN receptor, a cell surface transmembrane receptor 
composed of two subunits, IFN-α receptor 1 (IFNAR1) and IFNAR2 [218; 
219]. Binding of the IFNAR results in receptor subunit dimerization and 
activation of kinases that associate with their cytoplasmic tails: the Janus-
activated kinase 1 (JAK1) and tyrosine kinase 2 (TYK2). In turn, tyrosine 
phosphorylation activates the signal transducers and activators of 
transcription 1 and 2 (STAT1 and STAT2), to form a trimeric STAT1-
STAT2-IRF9 complex, also known as IFN-stimulated gene factor 3 
(ISGF3), as well as a STAT1 homodimer complex, known as the IFN-γ–
activated factor (GAF). Both complexes translocate to the nucleus and bind 
to DNA regulatory sequences containing IFN-stimulated response elements 
(ISREs) and IFN-γ–activated sites (GAS), respectively. The subsequent 
stimulation leads to the transcription of more than 100 IFN-stimulated 
genes (ISGs), whose concerted action leads to the generation of an 
‘‘antiviral state.’’ Although signaling through STAT1/STAT2 and 
STAT1/STAT1 dimers are the best characterized of the type 1 IFN-induced 
intracellular pathways to gene expression, cells can differ greatly in their 
signaling response to type 1 IFN, and a variety of other signaling pathways 
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can also be activated [218; 219]. The flexibility that receptors for type 1 
IFNs have for accessing downstream signaling molecules may be regulated 
by the relative abundance of STATs themselves [220]. 
 
 
Figure 11. The pathways to and from type 1 IFN are flexible. Families of 
sensors are available to detect viral products and induce expression of the 
cytokines. One set senses components in the cytoplasm. Another set is 
localized in cell membranes. There is also flexibility in the signaling 
pathways used by type 1 IFNs, with the potential to induce the activation of 
multiple STAT molecules and their downstream targets of transcription. 
(Sastre et al., 2006) 
1.6.2.1 Antiviral activities of ISGs 
The myxovirus resistance GTPase protein A (MxA), the protein kinase 
stimulated by dsRNA (PKR), the apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3G (APOBEC3G), and the oligoadenylate 
synthetases (OAS) are among the best characterized ISGs with antiviral 
activity. MxA is a guanosine triphosphatase (GTPase) belonging to the 
dynamin family that sequesters viral ribonucleoproteins to specific 
subcellular compartments. PKR is a serine-threonine kinase that 
phosphorylates downstream substrates upon recognition of dsRNA, 
including the elongation initiation factor eIF2α, resulting in the inhibition of 
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protein translation. APOBEC3G is a cytidine deaminase enzyme that exerts 
innate antiretroviral immune activity against retroviruses. The OAS proteins 
are also activated by dsRNA, leading to the generation of oligoadenylates, 
which activate ribonuclease L (Rnase L) that degrades cellular and viral 
RNA. Both PKR and the OAS/RNaseL systems have profound inhibitory 
effects on basal cellular processes that eliminate virus-infected cells by 
suicide [ 221 ]. Even in the absence of these IFN-regulated antiviral 
pathways, however, IFN can still induce an effective antiviral response 
[222]. The existence of other multiple ISGs with antiviral activity, multiple 
IFN genes, and multiple pathways leading to the production of IFN raises 
the intriguing question of whether hosts have evolved redundant pathways 
to make it generally difficult for viruses to use any single mechanisms to 
inhibit the IFN antiviral response or whether different factors of the IFN 
system mediate inhibition of specific virus families. 
1.6.2.2 Regulation of immune responses 
Type 1 IFNs extend their antiviral defense functions to a number of other 
immune response components. They amplify their own expression through 
two independent mechanisms: the induction of IRF7 and the accumulation 
of pDCs. These cytokines also activate natural killer (NK) cells to mediate 
elevated cytotoxicity [223] and induce interleukin-15 (IL-15) to promote NK 
cell proliferation [224]. At high concentrations, type 1 IFNs inhibit IL-12 
[224] and NK cell responsiveness for IFN-γ expression. All of these effects 
on innate immune responses depend on STAT1. Type 1 IFNs also regulate 
adaptive immunity. The early STAT1-dependent induction of IL-15 
contributes to short-term proliferation of memory CD8+ T cells [ 225 ]. 
However, only certain subsets of cells are equipped to respond to IL-15 
and, consistent with the anti-proliferative effects of type 1 IFNs, STAT1 acts 
to limit nonspecific CD8+ T cell expansion, at times overlapping with the 
induction of innate responses [226]. Hence, early during infections, the type 
1 IFNs work to enhance proliferation of certain cell subsets and inhibit 
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others through STAT1-dependent mechanisms. 
There are many other paradoxical effects assigned to type 1 IFNs, and 
some of these may be explained by regulation of accessibility to different 
signaling pathways. STAT1 is induced by the cytokines, and the protein 
concentrations of this molecule are elevated at times of type 1 IFN 
induction during viral infection [221]. These conditions may direct 
responses to STAT1/STAT2 and STAT1/STAT1 with induction of the 
antiviral defenses and general inhibition of proliferation as described above, 
but they also limit the ability of type 1 IFNs to activate STAT4 [221]. To be 
effective in defense, antigen-specific CD8+ T cells must expand in the 
presence of type 1 IFNs, and their IFN-γ production is aided by type 1 IFN- 
and STAT4- dependent events [221].  Thus, the elevated STAT1 levels, 
induced early during infection, and the consequences for proliferation and 
STAT4 accessibility, present inherent obstacles for generating protective T 
cell–mediated immunity. To overcome this, antigen-specific CD8+ T cells 
with lower relative levels of STAT1 are induced and preferentially undergo 
proliferation at times when STAT1 levels are elevated in most other cells 
[226]. Linking cytokine signaling to different pathways, depending on 
transcription factor levels, is a sophisticated means of providing cells with a 
variety of downstream options using only a limited number of genes. 
In addition to these effects during acute responses, the type 1 IFN receptor 
helps with long-term maintenance of the CD8 T+ cell pool [227]. Although 
the role for STAT1 in this effect has yet to be defined, its ability to inhibit 
proliferation may serve to protect CD8 T+ cells from chronic stimulation and 
eventual depletion through clonal ‘‘exhaustion’’ [228]. In the absence of 
STAT1, type 1 IFNs can induce growth as well as have anti-apoptotic 
effects on T cells through possible STAT3- and/or STAT5-dependent 
events [229; 230]. 
1.6.3. Viral Evasion of IFN Responses 
Many viruses dedicate a substantial part of their genomes to down-
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modulating the IFN pathways. A general mechanism used by several 
viruses is inhibition of cellular gene expression by inhibiting transcription, 
RNA processing, and/or translation [220]. Virus-induced shutoff of cellular 
protein expression not only favors the diversion of cellular resources for 
viral protein expression but also prevents the synthesis of IFN and of ISG 
products. Most viruses also encode viral products that specifically target 
pathways involved in the response to IFN, and such products are 
generically known as viral IFN antagonists. Typically, different virus families 
are characterized by the presence of specific viral IFN antagonists lacking 
homology with those from other families. Nevertheless, viral IFN 
antagonists focus inhibition on at least one of three key pathways: the 
IRF3, the JAK- STAT, and the PKR pathways. 
1.6.4. Virus and host relationship 
As we’ve described above, multiple offensive/defensive mechanisms have 
evolved to result in a balance between hosts and viruses, and type 1 IFNs 
have emerged as pivotal in this conflict (Figure 12). Antagonism of these 
cytokines appears to be a common feature shared by all viruses, and the 
variety of mechanisms for ‘‘hiding’’ from the direct antiviral effects of type 1 
IFNs provides the virus with opportunities to replicate and infect a new host 
before being eliminated by secondary innate and adaptive immune 
responses in the case of acute viral infections. In chronic infections, this 
can emerge as a means to establish viral persistence in the host. The 
diverse and multiple viral approaches to avoiding IFN induction and 
function provide persuasive evidence for the potency of these mediators in 
early defense. A direct consequence of disrupting the function of viral IFN 
antagonists is a decrease in viral replication and pathogenicity in the host. 
On the far side of the spectrum, however, viruses equipped with highly 
refined means of disrupting innate mechanisms activated by type 1 IFN are 
likely to be in the highest order of pathogenicity. High pathogenicity, 
however, is not necessarily advantageous for the virus: conditions that 
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result in too rapid a destruction of the host may have deleterious effects on 
long-term survival of an infectious agent that requires the host for further 
propagation. 
Although viruses evade the direct antiviral defense mechanisms activated 
by type 1 IFNs, hosts take advantage of these cytokines to elicit a wide 
range of responses. The classical signaling pathways used to induce direct 
antiviral defenses also activate some of these, particularly the ones elicited 
during innate periods of responses. The importance for protection is clearly 
shown by the fact that deficiencies in STAT1, and therefore in innate 
responses activated by type 1 IFNs, result in extreme sensitivities to viral 
infections [231; 232]. The host, however, has adapted to also use other 
signaling pathways to activate additional defense mechanisms, most clearly 
demonstrated for STAT4-dependent induction of T cell IFN-γ production. 
Thus, new complex and important defense responses have been attached 
to the critical early antiviral cytokines. One consequence of using these 
factors to promote downstream innate and adaptive responses is that, even 
if viruses have escaped their direct antiviral effects, the host can limit the 
window of opportunity for pathogen advancement. 
Much progress has been made, but there is still much to be learned about 
the pathways regulating IFN induction and function during viral infections. 
Nevertheless, there is evidence to conclude that, as in many difficult 
relationships, viruses and their hosts are learning to live together and that 
type 1 IFNs are important players in this compromise. 
 57 
 
Figure 12. The host uses type 1 IFNs to its advantage despite viral evasion 
mechanisms. The sensors for detecting viral products include components 
in the cytoplasm that are particularly sensitive to viral blocks. The set 
localized in cell membranes is available for sensing viral products before 
cells are infected. Once induced, the cytokines enhance innate and 
adaptive antiviral defense mechanisms as well as direct antiviral pathways. 
The intracellular signaling pathways used by type 1 IFNs appear to be 
modified to access a variety of downstream target effects in different 
immune cell subsets. The concentration of the various STAT molecules 
may act to shape accessibility to different signaling pathways. As a result of 
these events, an infectious agent overcoming the direct antiviral effects of 
type 1 IFNs has to deal with additional immune mechanisms of defense. 
(Sastre et al., 2006) 
1.7 HTLV-1 and innate immunity 
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As mentioned before, upon viral infection, several defense mechanisms 
cooperate to limit propagation of the pathogen within the organism. 
Classically, two types of immune responses have been defined: the innate 
response, rapidly engaged but transient and poorly specific, and the 
adaptive response, delayed but specific which allows the development of 
immune memory. 
All cells express receptors that are able to be viral sensors and to 
recognize structural motifs specifically present in pathogens (PAMPs). 
These sensors such as TLRs (Toll-Like Receptors) and RLHs (RIG-I-Like 
Helicases) are referred to as PRRs (Pattern Recognition Receptors). 
Interaction of the PAMPs with the PRRs triggers signaling pathways that 
lead to activation of IRF3 (Interferon Regulatory Factor 3) and IRF7 
transcription factors, eventually allowing transcription from the IFN-I 
promoters [233; 234]. 
IFN-I displays both autocrine and paracrine effects. Engagement of the 
IFN-I receptors (IFNAR-1 and IFNAR-2) at the cell surface induces 
activation of Jak1/Tyk2 and STAT1/STAT2 signaling cascade that 
subsequently promotes the expression of a large number of anti-viral 
effectors known as interferon-stimulated genes (ISGs) [235].  
IFN-I can be produced by all cells upon sensing virus infection, and in 
particular by innate immune cells such as macrophages and dendritic cells 
(DCs). These cells belong to the family of professional antigen-presenting 
cells. They have the capacity to capture antigens, process them and 
display them to lymphocytes [220]. Antigen presentation is therefore a 
central process in the immune response, since it allows priming of the 
adaptive response, thus bridging the innate and adaptive responses. For 
this reason, innate immunity is also essential for the activation of adaptive 
immunity. 
Plasmacytoid dendritic cells (pDCs) are the major IFN-I producers and they 
are found in an immature stage in the peripheral blood, and more 
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predominantly in inflamed tissues [236]. Myeloid dendritic cells (myDCs) 
circulate in the blood and constantly migrate into secondary lymphoid 
organs [220]. Many in vitro studies of DCs use myeloid-like DCs generated 
from CD14+ monocytes (Mo-mDCs), which unluckily are not identical to in 
vivo or ex vivo-purified DCs. Therefore, those results should sometimes be 
handled with caution [220]. 
In addition, other effectors of innate immunity such as restriction factors are 
present in cells before infection takes place and can act as immediate 
inhibitors of a given infectious agent [237]. When these proteins are not 
able to block viral spread, another efficient defense strategy consists of 
killing the infected cells. Members of both the innate system (natural killer 
cells) and the adaptive system (cytotoxic T lymphocytes) have the ability to 
kill infected cells. Invariant NKT (iNKT) cells are a small population of T 
cells that express cell surface antigens associated with the NK lineage. 
These cells display attributes of both innate and adaptive immunity, and 
modulate the immune response by secreting large amounts of cytokines. 
1.7.1 HTLV-1 infects cells that play a major role in the innate immune 
response 
As mentioned before, in vivo the HTLV-1 provirus is predominantly 
detected in CD4+ T lymphocytes [ 238 ], even if infection of CD8+ T 
lymphocytes [239; 240], and of B lymphocytes has also been documented. 
It thus appears that the main in vivo cellular targets of HTLV-1 are cells 
from the adaptive immune system. 
However, innate immune cells (monocytes, macrophages, DCs) are 
permissive to the virus in vitro and/or are infected in vivo [223; 241; 242] 
(Table 3). In vivo infection of DCs was demonstrated almost 20 years ago 
in HTLV-1-infected individuals [243]. Although myDCs and pDCs represent 
less than 1% of the cells in the peripheral blood, thus not significantly 
contributing to the total proviral load (PVL), their infection could greatly 
affect immune system function.  The determinants of  HTLV-1 proviral load 
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(the number of integrated copies of HTLV-1 expressed as a proportion of 
PBMCs) remains approximately stable in one individual over years, but 
may vary 1000- fold between individuals. A high proviral load is one of the 
best predictors of HAM/ TSP and ATL, although many patients with a high 
load will remain lifelong asymptomatic carriers. However, there is little 
longitudinal data to confirm that a high proviral load is the cause of disease 
rather than the consequence. Nevertheless, given the association between 
proviral load and disease a number of studies have attempted to elucidate 
the determinants of proviral load. 
1.7.1.1. Dendritic cells 
Until recently, the paradigm for HTLV-1 infection was a model in which viral 
transmission required cell-to-cell contact. Unlike most retroviruses, cell-free 
virions of HTLV-1 and other deltaretroviruses are very poorly infectious in 
vitro [244]. Cell-free HTLV-1 does not stably infect its primary target cells, 
CD4+ T cells, in vitro, although transient infection has been reported [245]. 
In 2008, Jones et al. demonstrated that both myDCs and pDCs could be 
productively infected in vitro by cell-free HTLV virions [7; 229]. Infected DCs 
rapidly and reproducibly transfer HTLV-1 to autologous primary CD4+ T 
cells, resulting in chronic productive infection of CD4+ T cells and 
generation of interleukin-2 (IL-2)-independent infected and immortalized 
transformed cells. Paralleling recent observations showed that HIV-1, 
although highly infectious as a cell-free particle, is more efficiently 
transmitted by DC–T cell interactions [246]. This led to the establishment of 
a model in which DCs that are present at the site of infection could be the 
primary target cells in a newly infected individual, allowing subsequent cell-
to-cell transmission of the virus to T cells (Figure 13). Whether these DCs 
are infected through cell-to-cell contact or by cell-free virus in vivo remains 
to be investigated. Factors that contribute to HTLV-1 dissemination, 
persistence and pathogenesis remain poorly understood.  
 
 Figure 13. Recently, the model of infection of HTLV
based on the observation of Jones 
efficiently infected by cell free virus 
the past, when the accepted model was based exclusively on cell
infection. Therefore, a new important role is prospected for DCs, which now 
could be the primary target of cell
subsequently transmit the virus to main target T
Many viruses infect DCs to facilitate their transmission, including the 
retroviruses HIV-1 and mouse mamma
viruses do this directly, hijacking the trafficking properties of DCs to 
facilitate their transport from the 
target cells. Viral infection of DCs can also indirectly facilitate spread b
impairing the ability of DCs to mount an appropriate immune response
[232]. 
These in vitro observations are supported by earlier 
250], indicating that they are direct
vivo. Studies of DCs isolated from HTLV
observations of efficient ex vivo infection of pDCs and myDCs, suggest that 
cell-free HTLV-1 can also infect DCs 
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observed also that HTLV-1 productively infects DCs and pDCs from an 
individual with HAM-TSP express HTLV-1 proteins, these findings confirm 
and extend earlier reports that DCs generated from monocytes from some 
individuals with HAM-TSP express viral proteins [233] and that DCs in 
infected individuals contain viral sequences [234]. High HTLV-1 proviral 
loads (4–37 copies per 100 cells) have been observed in pDCs isolated 
from asymptomatic individuals.  
For many viruses, infection of DCs affects the host’s ability to mount an 
appropriate immune response by interfering with DC development, 
maturation, function and/or viability [232]. A number of aspects of HTLV-1–
induced immunosuppression are consistent with alterations in DC function. 
Adaptive immunity is impaired in asymptomatic HTLV-1–infected 
individuals. Both Mo-mDCs generated from monocytes of HTLV-1–infected 
individuals and Mo-mDCs infected in vitro are poor stimulators of 
autologous T cell differentiation. HTLV-1 infection of DCs also interferes 
with innate immunity: pDCs isolated from HTLV-1– infected individuals are 
impaired in their ability to produce type I interferon [251], an important 
antiviral mechanism of the innate immune system. 
HTLV-1 infection of DCs may have an important role in the development of 
ATL and HAM-TSP. Individuals with ATL, like asymptomatic carriers, have 
impaired immune systems and development of ATL is associated with an 
increase in the number of HTLV-1– infected cells not recognized by CD8+ 
CTLs. In individuals with HAM/TSP, high viral loads are associated with 
decreased degeneracy of T cell recognition [252 ]. These observations 
suggest that, in both of these diseases, infection of DCs modifies the 
presentation of HTLV-1 antigens and thus generates a repertoire of CD8+ T 
cells that do not efficiently recognize the virally infected cells. Development 
of ATL is also associated with the loss of pDCs and myDCs [235], 
consistent with observations from other viruses that infection of DCs can 
induce cytopathic effects. 
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It was demonstrated also that infection of DCs is required to establish and 
maintain HTLV-1 infection in macaques model [82]. 
1.7.1.2. Monocytes and macrophages  
Monocytes and macrophages might also represent a putative virus 
reservoir in vivo. Koyanagi et al. showed that the PVL ranged between 0 
and 140 copies per 104 monocytes in a group of 22 HTLV-1- infected 
individuals [ 253 ]. Several studies hypothesized a latent infection of 
monocytes, which would allow them to escape immune recognition [254]. 
Viral reactivation could then be induced upon monocyte-to-macrophage 
differentiation. Infection of monocytes and monocyte-derived cells could be 
of particular interest in the context of mother-to-child transmission. Indeed, 
breast milk predominantly contains macrophages, rather than T cells. This 
could explain how prolonged breastfeeding leads to viral transmission. A 
recent article showed that an in vitro-infected breast milk macrophage cell 
line could transmit the virus to peripheral blood lymphocytes [ 255 ], 
supporting the hypothesis that these cells may be a viral reservoir.  
1.7.1.3. NK and iNKT cells  
Finally, HTLV-1 infection of activated NK cells was documented in vitro 
[256], but has not been demonstrated in vivo. Infection of iNKT cells was 
however recently demonstrated in vivo, in ACs and HAM/TSP patients 
[240]. The physiopathological consequences of putative NK infection and of 
iNKT infection have not been understood yet.  
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Table 3. Interplay between innate immune cells and HTLV-1. ND, not 
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1.8 Control of HTLV-1 replication by innate immune cells 
A recent in vitro study suggested that normal human pDCs are activated 
and able to secrete IFN-α  by a TLR-7-dependent mechanism when put in 
contact with concentrated purified HTLV-1 virions [257] (Figure 14). It is 
therefore possible that HTLV-1 activates pDCs and triggers their 
differentiation into killer pDCs [241]. These results suggested that infected 
human pDCs have an intact IFN-I induction pathway. 
Hishizawa et al., however, demonstrated that pDCs isolated from a small 
number of HTLV-1 ACs had impaired IFN-α production, consistent with 
previous observations reporting impaired immune function in some ACs 
[258; 259].  
Finally, Hishizawa et al. also found a negative correlation (Table 3) 
between the PVL in ACs and the ability of pDCs isolated from these 
individuals to secrete IFN-α  ex vivo [235]. Although further investigation is 
needed to demonstrate the causative relationship between both 
parameters, these results may indicate that efficient IFN-I production could 
limit viral replication and hence protect against a high PVL. Alternatively, 
another interpretation of this study is that when PVL increases, the number 
of infected pDCs also increases and therefore their ability to secrete IFN-I 
is lowered. 
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Figure 14. Interplay between HTLV-1 and the type-I interferon (IFN-I) 
induction pathway. Here we show simplified schematic of the TLR-induced 
IFN-I induction pathway. Recognition of PAMPs by TLR3 induces the 
recruitment of the adaptor molecule TRIF. TRIF activates via TRAF3 the 
kinases TBK1 and IKKε that phosphorylate IFR3 and IRF7 transcription 
factors. IRF3/7 heterodimers activate transcription of IFN-I (especially IFN-
β). This initial transcription and synthesis wave is followed by a second 
wave of IFN-α resulting from an amplification loop that involves IRF7. 
TLR7, 8 and 9, specifically expressed in pDCs, activate IRF7, which 
stimulates synthesis of IFN-α via MyD88, IRAK1/4 and TRAF6. (Sastre et 
al. 2006) 
1.9 Alteration of Innate Immune Cell Phenotype, Function and 
Abundance in the Context of HTLV-1 Infection 
Several studies were designed to monitor a possible functional alteration of 
innate immune cells, in the context of HTLV-1 infection. In a physiological 
situation, these cells are fully efficient if they are able to arise from 
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precursors in an adequate environment, become activated upon stimulation 
and differentiate into effectors cells. 
Some studies had shown that HTLV-1-infected macrophages and DCs 
could favor T cell proliferation [ 260 ]. This suggested that infection 
enhanced the antigen presentation and T cell-stimulation functions of DCs, 
potentially participating in the spontaneous T cell proliferation that has been 
observed in patients. However, this model was not supported in recent 
results, which demonstrated that monocytes isolated either from HTLV-1-
infected ACs, or individuals with ATLL or HAM/TSP, are deficient in their 
ability to differentiate into functional DCs [261]. Physiologically, activated 
DCs express high levels of adhesion molecules, MHC antigens and co-
stimulatory molecules, which all cooperate to potentiate the antigen-
presenting function of these cells, and their ability to induce activation of T 
lymphocytes. In addition, DCs derived from in vitro cultured infected 
monocytes express abnormal levels of surface activation markers, and are 
poorly able to activate autologous T lymphocytes.  
The impact of HTLV-1 infection on the number of DCs was assessed in 
vivo [235]. ATLL and HAM/TSP patients had a lower absolute number of 
myDCs and pDCs than uninfected individuals, while this was not the case 
for ACs. The correlation between DC number and clinical status suggests 
that the depletion of DCs could play a role in HTLV-1 physiopathology. It 
should however be emphasized that measurements of cell numbers were 
performed on peripheral blood samples. The observed depletion of DCs in 
the blood could be the consequence of a massive migration of DCs into 
tissues. 
1.10 Alteration of molecular pathways by HTLV-1 
1.10.1. Modulation of IFN-I Production 
IRF3 and IRF7 play essential roles in the early phase of IFN-I gene 
activation. IRF3 is constitutively expressed and activated through 
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phosphorylation by IKK and TBK1. This promotes the transactivation of 
downstream genes such as IFN-β. In contrast, IRF7 protein is synthesized 
de novo upon IFN stimulation and contributes to amplification of the IFN 
response, by inducing expression of IFN-α [262]. A very recent study of ex 
vivo CD4+ cells isolated from 30 HTLV-1-infected individuals (ACs, 
HAM/TSP, ATLL) demonstrated that SOCS1 (Suppressor Of Cytokine 
Signaling 1) is strongly up-regulated in ACs and patients with HAM/TSP but 
not in those with ATLL. This protein was previously shown to suppress IFN 
signaling by preventing STAT1 phosphorylation [263]. Interestingly, SOCS1 
expression correlated with HTLV-1 PVL in CD4+ cells of HAM/TSP patients. 
Tax was recently shown to promote the expression of SOCS1 in vitro. It 
was shown also that HTLV-1-infected cells that express viral mRNAs (and 
in particular tax) are likely to be impaired for early IFN induction signaling. 
The viral p30 protein was also shown to modulate innate cell activation 
[264]. Expression of p30 in human macrophages (i.e., the THP-1 cell line) 
alters TLR4 signaling, a critical pathway in the innate response to bacterial 
infection, and inhibits the production of pro-inflammatory cytokines normally 
secreted in response to TLR4 stimulation [248]. This altered TLR4 signaling 
is due to down-regulation of TLR4 expression and is mediated by an 
interaction-dependent inhibition of the transcriptional factor PU.1. p30-
mediated inhibition of pro-inflammatory signaling is accompanied by a 
stimulation of anti-inflammatory cytokine secretion such as IL-10, 
suggesting that p30 might interfere with the balance of pro- and anti-
inflammatory responses during bacterial infection. 
1.10.2. Modulation of IFN-I signaling 
Several reports showed that HTLV-1-infected cells still express IFNAR 
receptors [ 265 ]. However interestingly, HTLV-1 expression led to 
decreased Tyk2 and STAT2 phosphorylation, two major players in the IFN-I 
signaling pathways. This effect might be mediated through Gag or Protease 
expression. Downstream of Tyk2 and STAT2 phosphorylation, the active 
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ISGF3 complex (Interferon Stimulated Gene Factor 3), containing 
phosphorylated STAT1, STAT2, IRF9, and the CBP/p300 transcription co-
activators, triggers the expression of a number of genes. In addition to its 
effect on SOCS1, Tax overexpression also alters ISGF3 function by 
preventing interaction of the STAT2 component of ISGF3 with CBP/p300, 
therefore leading to modulation of the IFN-α transduction cascade [266]. 
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2. AIM OF THE STUDY 
In spite of over 30 years of study, several key features of the HTLV-1 
infectivity, viral persistence and pathogenesis remain obscure. 
It is well known that HTLV-1 primarily infects CD4+ T-cells and has been 
detected in ex vivo CD8+ T- cells, B-cells, monocytes and dendritic cells 
(DC) from infected individuals. DC and monocytes may contribute to viral 
persistence and pathogenesis. Several studies reported alteration in 
monocytes and DCs differentiation, activation and functions in HTLV-1 
infected patients. For example, Journo et al [268] showed that DCs isolated 
from HTLV-1-positive patient are associated with a defect of IFN-α upon 
stimulation and their ability to activate T-cells is impaired; these cells 
express also abnormal level of activation marker on the cell surface. 
p30 seems to play a key role during HTLV-1 infection of DCs. It was 
demonstrated that in the macaque model, the ablation of p30 expression 
severely affects infectivity. Furthermore, the infectivity of p30-KO in human 
primary monocyte-derived dendritic cells (Mo-mDCs) is severely impaired 
and is not persistent. 
Prior data demonstrated also that p30, by interacting with the cellular 
transcription factor PU.1 in human monocytes, affects TLR4 signaling and 
the expression of several genes involved in apoptosis, cell cycle, and 
transcription, pointing to p30 as a regulator of innate response to HTLV-1 
[264].  
The work described in the present thesis was aimed at understanding the 
role of HTLV-1 p30 during infection of human monocytes and dendritic 
cells. In particular we wanted: 
 to understand the mechanism by which p30 affects viral infectivity 
and persistence;  
 to study the effect of p30 on monocytes and dendritic cells (DC). 
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Indeed we hypothesized that p30 may affect not only TLR4 but also 
TLR3, TLR7 and 8 signaling in virus infected monocytes and in 
dendritic cells, and that by affecting the type 1 IFN response p30 
affects the activation and differentiation of these cells and ultimately 
the host response to the virus allowing viral replication and spread 
throughout the body. 
Thus, understanding how HTLV-1 evades the innate host response and 
affects immune activation/inflammation is of importance to gain more 
understanding on its oncogenicity and ability to induce autoimmune 
manifestations. 
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3. MATERIAL AND METHODS 
3.1 Cell lines 
The 729-6 B-cell lines infected with the pACH HTLV-1 wildtype (WT) virus 
and p30-KO viral mutants were maintained in RPMI 1640, 10% fetal bovine 
serum (FBS) and used as a source of virus to infect other cell types. In the 
case of leukemic monocyte-like THP-1 human cell line, the same media 
was supplemented with 50 µM β-mercapto-ethanol. To stimulate THP-1 
cells we used 50 ng/ml phorbol myristyl acetate (PMA) for 3 hours (Sigma, 
St. Louis, MO, USA). We used TLR agonists to study ISGs expression in 
HTLV-1 infected THP-1 cells such as 20 ng/ml lipopolysaccharide (LPS) 
(List Biological Laboratories Inc., Campbell, CA, USA), 10 µg/ml poly(I:C) 
HMW (InvivoGen, San Diego, CA, USA) or Imiquimod (InvivoGen, San 
Diego, CA, USA). 
3.2 Primary human cells 
3.2.1 Separation of monocytes by adhesion 
Primary human monocytes were obtained from heparinized human 
peripheral blood from healthy donors. Whole blood was stratified by 
gradient using Ficoll-Paque Plus (GE Healthcare, Chalfont St. Giles, UK) 
and centrifuged at 2300 rpm for 25 min. Cells were collected and washed 
with PBS (1900 rpm for 10 min). The number of viable leukocytes was 
determined by trypan blue exclusion. Human monocytes were separated by 
adhesion after 6 hours and resuspended in RPMI 1640, 10% FBS. We 
used TLR agonists to study ISGs expression in HTLV-1 infected primary 
monocytes such as 20 ng/ml lipopolysaccharide (LPS) (List Biological 
Laboratories Inc., Campbell, CA, USA), 10 µg/ml poly(I:C) HMW 
(InvivoGen, San Diego, CA, USA) or Imiquimod (InvivoGen, San Diego, 
CA, USA). 
3.2.2 Separation of monocytes by elutriation 
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To obtain primary monocyte-derived dendritic cells (Mo-mDC), monocytes 
were alternatively separated from PBMCs by elutriation to keep them 
inactivated and left “untouched”. Elutriation is a process that allow to 
separate particles based on their size, shape and density, using a stream of 
gas or liquid flowing in a direction usually opposite to the direction of 
sedimentation (Figure 1). 
The centrifuge was run at 20 °C and constant speed (1000 rpm). The pump 
was turned on and the system was washed first with 200 ml of 70% 
ethanol, then with 200 ml of PBS to remove traces of alcohol. PBS was 
then replaced by freshly made elutriation fluid at an initial flow rate used for 
the introduction of cells into the chamber. The further run serves to remove 
bubbles from the system. After instrument preparation, PBMCs were placed 
into a specially designed centrifuge rotor/chamber and subjected to 
centrifugal field. The cells were then sequentially washed out of the rotor 
based on their size, using a buffer stream that flows in the direction 
opposite the centrifugal field at permanent flow rate of 7ml/min. By 
balancing centrifugal force against the opposing buffer flow, we could 
collect lymphocytes in the first 4-5 tubes, which are about 6-8 µm. When 
effluent is clear, the dial of pump was increased by 0.05 unit increments for 
each of the next 3 fractions. Around tube 8 you are collecting monocytes, 
which are 8-10 µm. Then cells were checked for the purity (>98% CD14+).  
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Figure 1. Schematic representation of elutriation process. 
3.2.1.1. Differentiation of Mo-mDC 
Elutriated monocytes were then differentiated in approximately seven days 
of culture in RPMI 1640, 20% BIT (Stem Cell Technologies, Vancouver, 
Canada) with 50 ng/ml IL-4 (Peprotech, Rock Hill, NJ, USA), 50 ng/ml GM-
CSF (Peprotech, Rock Hill, NJ, USA) and 10 ng/ml Transforming growth 
factor- β (TGF-β) (R&D systems, Minneapolis, MN, USA). Mo-mDC purity 
was checked by phenotype using CD14-, CD3-, CD19-, CD1a+, and CD11c+ 
Ab by flow cytometry. We used TLR agonists to study ISGs expression in 
HTLV-1 infected Mo-mDC such as 20 ng/ml lipopolysaccharide (LPS) (List 
Biological Laboratories Inc., Campbell, CA, USA), 10 µg/ml poly(I:C) HMW 
(InvivoGen, San Diego, CA, USA) or Imiquimod (InvivoGen, San Diego, 
CA, USA). 
3.3 HTLV-1 mutagenesis in 729-6 cell line 
Mutations to ablate p12 and p30 were introduced in the ClaI/SalI cassette from the 
HTLV-1 molecular clone pBST that include the orf-I and the orf-II. The 
molecular clone pACH was cleaved at the ClaI/SalI to generate the 
backbone for the construction of all viral mutants. The pBST ClaI/SalI 
cassette was ligated to the pACH backbone to obtain the wild-type HTLV-1 
clone. Mutations to ablate p30 were introduced into the pBST cassette. To 
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generate the p30 knockout (KO) mutant, we replaced the leucine in position 
3 (CTA) of p30 with a termination codon (TAA). The mutant was generated 
with the use of complementary mutant site-specific primers, the Phusion 
enzyme, and mastermix (Finnzymes; New England Biolabs), where the 
reaction in the thermocycler was followed by DpnI digestion before 
transformation of One Shot Max Efficiency DH5α (Invitrogen). The following 
DNA primers were used to generate the mutant clone:  
 p30ko forward, 5’-CCTGCATTTTTTCTTTCCTAGCATAATGGTGT- 
TTCGCCTTAAAAGCCCCT-3’; p30ko reverse, 5’-
AGGGGCTTTTAAG- 
GCGAAACACCATTATGCTAGGAAAGAAAAAATGCAG-3’;  
 WT-forward 5’- 
TGCTTTCTCCGGGCGACGTCAGCAGCCTTCTTCTC-3’; and WT- 
reverse, 5’-GCGGAGAAGAAGGCTGCTGACGTCGCC-3’.  
The mutant clones were inserted into the pH6neo vector, and all the 
resulting clones were verified by DNA sequencing of the ClaI/SalI fragment 
inserted in the provirus. 729-6 human lymphoblastoid B cells (5 x 106) were 
electroporated with 5 ug of WTneo or 30KOneo with the use of AMAXA 
(Amaxa Biosystems) according to the manufacturer’s guidelines. Infected 
cells were selected by culture in neomycin. Stable 729 B-cell lines 
expressing each mutant, and the cell lines expressed equivalent levels of 
p19 Gag in the supernatant were thus generated and subsequently use as 
a source of virus to infect THP-1 cells. 
3.4 Virus infection 
HTLV-1-WT or –p30-KO producer 729-6 B-cell lines were used to harvest 
HTLV-1 virions. The supernatants of such cell lines were collected and 
ultra-centrifuged at 23000 rpm for two hours and thirty minutes to isolate 
the virions, which then were resuspended in PBS. In order to enhance the 
infectivity, as THP-1 cells are hard to infect, we spin-infected THP-1 cells at 
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3000 rpm for one hour in presence of 8 µg/ml polybrene (Sigma, St. Louis, 
MO, USA). Infected cells were then resuspended in RPMI 1640, 10% FBS 
supplemented with 50 µM β-mercapto-ethanol and kept in culture for 
several weeks.   
3.5 Lentiviruses Transduction of THP-1 cells 
In order to efficiently express p30 or p12/p8 proteins, THP-1 cells were 
transduced with lentiviral vectors based on Naldini’s system. This method 
consists in the use of 3 different plasmid: two packaging plasmid that are 
pSAX (gag/pol) and pDM2.G (env) and one lenti construct (pSDM101 
expressing GFP) with a capside-like sequence and a polylinker sequence 
were viral genes (p30 or p12/p8) were inserted. The lenti construct with p30 
and p12/p8 plasmid expresses the fusion protein of HTLV-1 p30 or p12/p8 
tagged with the influenza hemagglutinin (HA1) tag. In order to produce 
lentiviruses, pSDM101 (expressing GFP only) or pSDM101-p30 (co-
expressing GFP and HTLV-1 p30) or pSDM101-p12/p8 (co-expressing 
GFP and HTLV-1 p12/p8), pDM2.G and pSAX were transduced 293T-cells 
with LipoD293 (Signagen, Rockville, MD, USA) according to manufacturer’s 
instruction. The supernatant was harvested, 0.22µm filtered and used 
during spin-infection, as described above. Efficiency of transduction was 
checked by flow-cytometry and ranged between 80% and 95%.   
3.6 Detection of virus productions by ELISA  
The production of HTLV-1 in the supernatant of the infected cell cultures 
was assessed by measuring the amount of MA (p19 Gag) protein by ELISA 
(Zeptometrix, Buffalo, NY, USA). Supernatants were initially treated with 
Lysing Buffer (1:10). HTLV antigen standards were prepared diluting 1:2 
the given solution obtaining concentrations from 800pg/ml to 0pg/ml. 
Standards and samples were distributed in duplicate and incubated for 2 
hours at 37 °C. Then the microplate was washed 6 times with Wash Buffer 
1X and then HTLV Detector Antibody was added to each well and 
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incubated for 1 hour at 37 °C. After washing the plate, Peroxidase was 
added to the plate and incubated for 1 hour at 37 °C. Then the plate was 
washed and Substrate Solution was added into each well and incubated 
uncovered for 30 min at room temperature (RT). A blue color developed in 
wells containing viral antigen. The reaction was stopped adding Stop 
Solution resulting in a color change from blue to yellow. The optical density 
of each well at 450nm was read using a microplate reader (Victor Wallac 
Perkin Elmer) within 15 min.  
3.7 Detection of HTLV-1 proviral load 
HTLV-1 proviral load was measured in the various cell lines. Real-time 
PCR was performed on genomic DNA extracted from different cell lines 
with the DNeasy tissue kit, according to the manufacturer’s protocol. The 
QIAGEN method was used for the DNA elution stepin with 10mM Tris 
(tris(hydroxymethyl)aminomethane; pH8.0). The quantity and quality of the 
DNA were assessed by Nanodrop. Five hundred nanograms of genomic 
DNA was subjected to real-time PCR. The TaqMan probe and PCR primers 
for the real-time PCR were designed within the integrase gene of HTLV-1 x 
1MT. The sequence of the TaqMan probe was: 5’-TGT 
CCACCTGCCATTAAGCCCGA-3’, the DNA primers sequences used had 
the following sequence: 
 forward 5’-GCAGAGGAGGAAATTACCCAGTAC-3’; reverse 5’-
CAATTTTACCCAGGCATTTAATGT-3’.  
Reaction conditions were as follows: the 25 µL of PCR mixture for HTLV-1 
and cells albumin DNA consisted of 500 ng of DNA extracted from PBMCs; 
200nM primers; 100nM probe; 2X TaqMan Universal PCR Mastermix 
(Applied Biosystems) which consists of 10mM Tris-HCl (pH 8.3); 50mM 
KCl; 5mM MgCl2; 300µM each of deoxyadenosine triphosphate, 
deoxycytidine triphosphate, and deoxyguanosine triphosphate; 600µM 
deoxyuridine triphosphate; 0.625 U of AmpliTaq Gold DNA polymerase; 
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and 0.25 U of uracil N-glycosylase. Used for HTLV-1 and cells albumin 
DNA amplification, 1 cycle at 50°C for 2 minutes and 1 cycle at 95°C for 10 
minutes were followed by a 2-step PCR procedure consisting of 15 
seconds at 95°C and 1 minute at 60°C for 50 cycles. The amplification was 
performed with the ABI Prism 7500 Sequence Detector system (Applied 
Biosystems). The normalized value of the HTLV-1 proviral DNA load was 
calculated as HTLV-1 DNA copy number/albumin gene copy number and 
expressed as the number of HTLV-1 proviral DNA copies per 106 cells. 
3.8 Flow cytometry 
In order to determine the surface expansion of specific markers on the 
THP-1 cell lines, primary monocytes or Mo-mDC, phenotype was assessed 
by flow cytometry. Cells were incubated with the proper antibodies for 
fifteen minutes at room temperature, then washed in PBS and fixed in 1% 
paraformaldehyde, run on LSR II (BD Bioscience, San Jose, CA, USA) and 
analyzed with FlowJo (Tree Star Inc., Ashland, OR, USA). In the case of 
intracellular cytokine staining, 1µg/ml of the protein transport inhibitor 
Brefeldin A (BD, San Jose, CA, USA) was added to the culture 16 hours 
before the analysis. Then cells were stained for surface markers as 
described above and then permeabilized with Saponin 1% and stained with 
the proper intracellular cytokine antibody for 45 min at 2-8 °C. Then cells 
were washed in PBS and fixed in 1% paraformaldehyde, run on LSR II and 
analyzed with FlowJo. The antibodies used were CD14 (Biolegend, San 
Diego, CA, USA), CD80, CD83, CD86, TNF-α, CCR7 (BD Bioscience, San 
Jose, CA, USA), IL12 (eBioscience, San Diego, CA, USA), TLR4.  
3.9 Quantification by real-time PCR of ISGs expression  
For real-time PCR, total RNA was extracted from cells and retro-transcribed 
(Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. 
Reactions were performed using a SYBR Fast qPCR mix 
(KapaBiosystems, Woburn, MA, USA). The primer sequences were (5’-3’):  
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• 18s: forward 5’-GCCCGAAGCGTTTACTTTGA-3’, reverse 5’-
TCCATTATTCCTAGCTGCGGTATC-3’;  
• MxA: forward 5’-AGGAGTTGCCCTTCCCAGA-3’, reverse 5’-
TCGTTCACAAGTTTCTTCAGTTTCA-3’;  
• APOBEC3G: forward 5’-CCGTCTGGGTGTGCTACGAA-3’, reverse 
5’-GCTTCCTCCACTTGCTGAACCA-3’;  
• OAS: forward 5’-CAGTCCTGGTGAGTTTGCAGT-3’, reverse 5’-
GCCAGTGCTTTATCAAGAGGAT-3’.  
Used for 18s and ISGs cDNA amplification, 1 cycle at 95°C for 10 minutes 
was followed by a 3-step PCR procedure consisting of 10 seconds at 95°C, 
15 seconds at 59°C and 20 seconds at 72°C for 40 cycles. The 
amplification was performed with Rotor Gene Q (Quiagen). 
Results were expressed as ∆∆Ct and presented as ratios between the 
target gene and the 18s housekeeping mRNA.  
3.10 Immunoblot analysis 
To evaluate the expression of viral proteins or tubulin as a control, THP-1 
or Mo-mDC cells were lysated with Lysis buffer. Proteins concentration was 
measured with Bradford method and 20 µg of total proteins for each sample 
were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (4–12%) in MES SDS running buffer (Invitrogen, Carlsbad, 
CA, USA). The ratio charge/mass is constant for the presence of the SDS; 
the separation takes place on the basis of the effects of molecular size due 
to the size of the meshes of the gel. The smaller proteins pass through 
more easily, while frictional forces delay those of larger size. The run was 
performed for 1 hour at 150V. When the gel finished to run, proteins were 
transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA) for 1 
hour at 230mA in buffer containing 25 mM Tris, 192 mM glycin and 15% 
(v/v) methanol. The membranes were blocked with PBS, 0.1% Tween and 
4% nonfat dried milk, for 30 min at room temperature and then they were 
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probed with primary antibody directed to the HA-tag or the tubulin overnight 
at 2-8°C and the proper horseradish peroxidase (HRP)-conjugated 
secondary antibodies was used for detection for 1 hour at room 
temperature. As HRP substrare SuperSignal West Pico chemiluminescent 
substrate (Pierce, Rockford, IL, USA) was used. 
3.11 ChIP assay 
ChIPs were performed as follows. Briefly, for each chromatin preparation, 
5x107 cells were resuspended in 50 ml of medium without FBS and cross-
linked in 1% formaldehyde for 10’ at RT'. Cross-linking was quenched by 
125mM glycine, 5’ at RT. Cross-linked cells were then washed with ice-cold 
PBS and resuspended in ice cold RIPA buffer (10mM Tris-HCl pH8, 140 
mM NaCl, 1mM EDTA pH 8, 0.5mM EGTA, 1% Triton X-100, 0.3% SDS 
and 0.1% Sodium Deoxycholate) to a final concentration of 5x106 cell/ml. 
DNA was sheared with a Misonix XL sonicator, by performing 12 x 30 
seconds sonication cycles at power setting of 5. For each single 
immunoprecipitation, 5×106 chromatin cell equivalents in the 200-500 bp 
range were immunoprecipitated with 5µg of the following antibodies: anti-
HA, anti-RNA-Polymerase II (Pol II), anti-RNA-Polymerase II 
phosphoSerine5 (Pol II-S5) (Abcam), anti-RNA-Polymerase II 
phosphoSerine2 (Pol II-S2) (Covance) and anti-PU.1 (Cell Signalling. 
Parallel ChIPs were run with a Flag M2 antibody used as negative control 
(Sigma). Immunoprecipitation-enriched DNAs were used to perform real-
time PCR.  
Oligonucleotides were designed to specifically target and quantify the 
promoter region of: 
• interferonα1 (IFNα1) (forward 5’-GGAACAAGATGGGGAAGACA-3’, 
reverse 5’-GCAGATACTTCTGGGCTTGC-3’),  
• IFNα2 (forward 5’-AAGGCTCTGGGGTAAAAGA-3’, reverse 5’-
GACCTTGCTTTGTGCCTAGC-3’), 
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•  IFNβ (forward 5’-AGGACCATCTCATATAAATAGGCCATACCC-3’, 
reverse 5’-ACTGAAAATTGCTGCTTCTTTGTAGGAATC-3’), 
•  TLR4 (forward 5’-GCCAACTAGCTTCCTCTTGCTG-3’, reverse 5’-
CACCGTCTGACCGAGCAGTT-3’) 
•  Ubiquitin B (forward 5’-GAAGGAAGAGAAGCGCATAGAGGAGAA-
3’, reverse 5’-CTCATAGCCGTAAGAAAGGCTCCTAAA-3’).  
The ∆Ct method was used to calculate ChIP Q-PCR enrichments. 
3.12 Statistical analysis 
Anova tests with Bonferroni post-tests were performed with the informatics 
support of Graphpad Prism 5. 
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4. RESULTS AND DISCUSSION 
4.1 THP-1 lentivirus transduction  
Since the cells we want to work with (THP-1 monocytic cell line) are hard to 
transfect, we generated lentiviruses to transduce HTLV-1 regulatory 
proteins (p30 or p12/p8) in the target cells. Using a third generation 
Naldini’s systems we produced in 293T lentivirus coexpressing both p30 
and GFP (p30 LV), p12/p8 and GFP (p12/p8 LV) or GFP only (CTRL LV) to 
monitor the infection.  
We transduced THP-1 cells with these lentiviruses: CTRL LV, p30 LV or 
p12/p8 LV. To control the efficiency of the transduction after 72 hours we 
observed the cells with fluorescence microscopy. As we can see in the 
figure below most of the cells are green compared to the imagine in bright 
field (Figure 1, left panel) proving a good efficiency of transduction. Then, 
using flow cytometry we measured the expression of GFP in THP-1 
lentivirus transduced cells. As we can see in the histogram below these LV 
are able to infect THP-1 cells with an efficiency spanning from 70 to over 
90% (Figure 1, right panel). 
 
 
 
 
Figure 1. Flurescence microscopy of LV transduced THP-1 cells (left 
panel). Flow cytometric analysis of THP-1 cells expressing lentiviruses. 
GFP expression in the cells was assessed before (red line) and after 72 
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hours of transduction (blue line) (right panel). 
4.1.1 Cellular localization of p30 in LV transduced THP-1 cells 
After that we wanted to confirm the appropriate localization of p30 in THP-1 
cells transduced with p30 expressing lentivirus. The p30 plasmid expresses 
the fusion protein of HTLV-1 p30 tagged with the influenza hemagglutinin 
(HA) tag that should simplify the detection of p30 but it could affect the 
appropriate localization of the protein. We used confocal microscopy to 
confirm the exact localization of p30. As we can see from the figure below, 
the p30 protein produced by p30LV transduced THP-1 cells, correctly 
localizes in the nucleus and mainly in the nucleoli (Figure 2), as reported in 
the literature [162].   
 
 
Figure 2. Confocal microscopy of p30LV transduced THP-1 cells. We 
performed different staining: with anti HA-antibody (p30HA), with a 
nucleolar marker (NucleoPhosmin), with a nuclear colorant (DAPI). 
4.2 TLR4 expression in lentiviruses transduced THP-1 cells 
It is known that HTLV-1-p30 protein interacts in the nucleus with PU.1 and 
is able to repress toll-like receptor 4 (TLR4) expression on the cell surface 
[264]. At first we verified if in our experimental conditions p30 affected TLR-
4 expression. In order to do that, we transduced THP-1 cells with control 
lentiviruses  (CTRL LV; gray line) or p30 lentivirus (p30 LV; red line).  
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TLR4 expression on the cell surface of transduced cells was analyzed by 
flow cytometry before and after 3 hour of stimulation with phorbol myristyl 
acetate (PMA). While untreated (-PMA) p30- or control-transduced THP-1 
cells showed a similar level of TLR4 expression of the cell surface (left 
panel, Figure 3), treated cells (+PMA) showed an upregulation of TLR-4 
expression in the control but not in the p30-transduced THP-1 cells (Fig. 3, 
middle panels). We then study on the same transduced and PMA treated 
cells the expression of CD14 surface marker, used as a control, by flow 
cytometry. As previously published [264], the CD14 surface marker 
expression, was not affected by p30 (Fig. 4, right panel) as the expression 
was the same in mock- transduced and p30 transduced THP-1 cells upon 3 
hours of PMA stimulation. 
 
Figure 3. Flow cytometric analysis of THP-1 cells transduced with 
p30 (red line) or control (gray line) lentivirus. TLR4 expression on 
the cell surface was assessed following stimulation with PMA or not 
(left panel). The CD14 surface marker was used as a control (right 
panels). 
 
To understand the mechanism that causes this downregulation of TLR4 
expression, we performed a quantitative real-time PCR on TLR4 mRNA on 
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CTRL transduced and p30 transduced THP-1 cells. We confirmed that the 
mechanism underlying the effect of p30 was transcriptional (Figure 4).  As 
we can see here, the expression of TLR4 mRNA was statistically significant 
decreased in presence of p30 protein upon PMA stimulation. In untreated 
cells (-PMA), we didn’t observe any difference between THP-1 cells 
transduced with CTRL lentivirus or p30 lentivirus. 
 
Figure 4: Real-time PCR was performed on the TLR4 mRNA in THP-1 
cells transduced with p30- (in red) or control (in gray) lentivirus with or 
without PMA stimulation. The results are shown as a percentage of relative 
expression of the PMA stimulated mock-transduced cell. The statistically 
significant differences are marked with a star, which indicates a p value 
less than 0.0001. 
4.3 Cytokines expression in lentiviruses transduced THP-1 cells 
upon LPS stimulation 
Similarly, we transduced THP-1 cells with p30 lentivirus or with the control 
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lentivirus and after 18 hours of LPS stimulation, cells were collected and 
analyzed by flow cytometry for intracellular production of IL-12 and TNF-α 
(Figure 5). In both cases, the presence of p30 decreased the expression of 
such cytokines upon LPS stimulation when compared with the control.  
 
Figure 5: Flow cytometric analysis of THP-1 cells transduced with p30 (red 
line) or mock transduced (gray line). Twelve hours following LPS 
stimulation, cells were collected and analyzed for intracellular production of 
IL-12 and TNF-α. 
 
These data are consistent with the finding of Datta and colleagues [264], 
which demonstrated that p30 decreases the release of pro-inflammatory 
cytokines, such as TNF-α, IL-8, and MCP-1 upon stimulation with the TLR4 
specific agonist lipopolysaccharide (LPS) by decreasing the expression of 
TLR4 itself.  
4.4 Expression of interferon stimulated genes (ISGs) in 
lentiviruses (p30 or CTRL) transduced THP-1 cells upon 
stimulation with TLR agonists 
We next studied the effect of p30 on TLR3 and TLR7/8 because of their 
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relevance in virus immune-surveillance, since they recognize the double 
and the single strand RNA (dsRNA or ssRNA) respectively, which are 
characteristic of viral infections and particularly they are intermediates of 
HTLV-1 infection. As type 1 IFNs are the most potent innate antiviral factors 
able to stimulate the production of a wide variety of antiviral interferon 
stimulated genes (ISGs); and as both DNA and RNA viruses, as well as 
other pathogens have evolved a sophisticated and varied strategy to 
counteract these innate protective responses; we analayzed the expression 
of three ISGs after TLR stimulation with specific agonists.  
In order to do that THP-1 cells were p30- or mock-transduced with the 
same lentiviruses used before, then stimulated with specific agonist of 
TLR3, such as polyI:C, or specific agonist of TLR7/8, such as Imiquimod. 
LPS stimulation on TLR4 was used as a control. We analyzed by real-time 
PCR the level of mRNA expression of interferon stimulated genes (ISGs) 
and selected the most common ISGs to measure the overall type I 
interferon response, such as myxovirus resistance A (MxA), APOBEC-3G 
(A3G) and 2’-5’-oligoadenylate synthetase (OAS). The results are shown in 
terms of percentage of relative expression of these ISGs genes, in the 
presence of p30 expression versus the mock-transduced control following 6 
hours of TLR3 and -4 stimulation. Following the polyI:C stimulation, MxA 
and OAS expression was significantly inhibited by p30, and this difference 
was significant also when the expression of all genes together were 
analyzed (p<0.01) (Figure 6). 
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Figure 6: Real-time PCR quantitative analysis of type-1 interferon 
stimulated genes (ISGs). THP-1 cells were transduced with p30- (red bars) 
or control lentivirus (gray bars), kept in culture for 72 hours and stimulated 
for six hours with polyI:C. The results are presented as the percentage of 
inhibition of the expression of the MxA, A3G and OAS mRNAs versus the 
mock-transfected control. The statistically significant differences are 
marked with one or two stars, which indicate a p value less than 0.01 or 
0.0001, respectively.  
 
A similar effect was observed following LPS stimulation (Figure 7), as 
expected. 
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Figure 7: Real-time PCR quantitative analysis of type-1 interferon 
stimulated genes (ISGs). THP-1 cells were transduced with p30- (red bars) 
or control lentivirus (gray bars), kept in culture for 72 hours and stimulated 
for six hours with LPS The results are presented as the percentage of 
inhibition of the expression of the MxA A3G and OAS mRNAs versus the 
mock transfected control. The statistically significant differences are 
marked with one or two stars, which indicate a p value less than 0.01 or 
0.0001, respectively.  
 
Surprisingly, no difference was found following stimulation with Imiquimod 
(Figure 8).  
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Figure 8: Real-time PCR quantitative analysis of type-1 interferon 
stimulated genes (ISGs). THP-1 cells were transduced with p30- (red bars) 
or control lentivirus (gray bars), kept in culture for 72 hours and stimulated 
for six hours with Imiquimod the results are presented as the percentage of 
inhibition of the expression of the MxA A3G and OAS mRNAs versus the 
mock transfected control.  
4.4.1 Expression of proteins in lentiviruses transduced THP-1 cells 
upon stimulation with TLR agonists 
To control if these differences observed in the expression of ISGs were 
caused by a different expression of quantity of proteins, we performed and 
immunoblot assay using antibody able to recognize p30 and tubulin as a 
control. The lack of p30- mediated inhibition of Imiquimod was not due to 
difference in the expression of p30, as demonstrated in Figure 9.  
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Figure 9: Immunoblot analysis of tubulin and p30 expression of the 
experiments presented in Figure 5; 6 and 7. 
4.5 Expression of interferon stimulated genes (ISGs) in 
lentiviruses (p12/p8 or CTRL) transduced THP-1 cells upon 
stimulation with TLR agonists 
Similar experiments were performed using cDNA endcoding p12/p8 since 
the presence of these proteins is essential for infectivity of monocytes as 
well [81]. So THP-1 cells were p12/p8- or mock-transduced, then stimulated 
with specific agonist of TLR3, such as polyI:C, or specific agonist of 
TLR7/8, such as Imiquimod. LPS stimulation on TLR4 was used as a 
control. We analyzed by real-time PCR the level of mRNA expression of 
interferon stimulated genes (ISGs) such as myxovirus resistance A (MxA), 
APOBEC-3G (A3G) and 2’-5’-oligoadenylate synthetase (OAS). In contrast 
to p30, p12/p8 did not have a significant effect on the ISGs upon specific 
TLR3 (Figure 10A), TLR4 (Figure 10A) and TLR7/8 (Figure 10C) 
stimulation.  
 95 
 
 
 
 
 
 96 
 
Figure 10. Real-time PCR quantitative analysis of type-1 interferon 
stimulated genes (ISGs). THP-1 cells were transduced with p12/p8- (green 
bars) or control lentivirus (gray bars), kept in culture for 72 hours and 
stimulated for six hours with polyI:C (A), LPS (B) or Imiquimod (C). The 
results are presented as the percentage of inhibition of the expression of 
the MxA A3G and OAS mRNAs versus the mock-transfected control.  
4.6 Expression of interferon stimulated genes (ISGs) in 
lentiviruses transduced human primary cells 
To validate the results obtained in the human tumor THP-1 cell line with 
p30, we performed the same experiments on ex vivo primary human 
monocytes and in vitro primary human Mo-mDCs. 
4.6.1 Expression of ISGs in LV transduced primary human monocytes  
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll 
gradient and primary monocytes were separated by adherence for 6 hours. 
Monocytes were transduced with p30 or CTRL lentivirus, and stimulated for 
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6 hours with polyI:C, LPS or Imiquimod. The expression of the three ISGs 
analyzed was significantly inhibited by the presence of p30 upon 
stimulation with polyI:C (Figure 11). 
 
 
 
Figure 11. Real-time PCR quantitative analysis of the expression of (ISGs) 
on primary monocytes was performed. Primary monocytes were 
transduced with p30- (red bars) or control lentivirus (gray bars). 72 hours 
later the cells were stimulated with polyI:C. The results are shown as 
percentage of relative expression of ISGs mRNAs, such as MxA, A3G and 
OAS, following 6 hours of TLR stimulation. The statistically significant 
differences are marked with one or two stars, which indicate a p value less 
than 0.01 or 0.0001, respectively. 
 
A similar effect was observed following LPS stimulation, as expected 
(Figure 12). 
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Figure 12. Real-time PCR quantitative analysis of the expression of (ISGs) 
on primary monocytes was performed. Primary monocytes were 
transduced with p30- (red bars) or control lentivirus (gray bars). 72 hours 
later the cells were stimulated with LPS. The results are shown as 
percentage of relative expression of ISGs mRNAs, such as MxA, A3G and 
OAS, following 6 hours of TLR stimulation. The statistically significant 
differences are marked with one or two stars, which indicate a p value less 
than 0.01 or 0.0001, respectively. 
 
The expression of ISGs MxA, OAS and A3G was not significantly inhibited 
by the presence of p30 upon stimulation with Imiquimod (Figure 13). 
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Figure 13. Real-time PCR quantitative analysis of the expression of (ISGs) 
on primary monocytes was performed. Primary monocytes were 
transduced with p30- (red bars) or control lentivirus (gray bars). 72 hours 
later the cells were stimulated with Imiquimod. The results are shown as 
percentage of relative expression of ISGs mRNAs, such as MxA, A3G and 
OAS, following 6 hours of TLR stimulation.  
 
These data were consistent with our observations in THP-1 cells. 
4.6.2 Expression of ISGs in LV transduced monocyte-derived dendritic 
cells (Mo-mDCs)  
In the case of Mo-mDCs, after isolation of PBMCs by Ficoll gradient, 
primary monocytes were separated by elutriation to keep them inactivated 
and left “untouched”. After seven days of differentiation with IL4, GM-CSF, 
and TGFβ [81], the cell phenotype was verified by flow cytometry (data not 
shown) and cells were transduced with p30 or mock-transduced 
lentiviruses, and stimulated with polyI:C or LPS. Expression of p30 inhibited 
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significantly the mRNA expression of all the ISGs studied following 
stimulation with polyI:C as demonstrated in Figue 14.  
 
 
Figure 14. Real-time PCR quantitative analysis of the expression of (ISGs) 
on Mo-mDC was performed. Primary elutriated monocytes were 
differentiated into Mo-mDC and transduced with p30- (red bars) or control 
lentivirus (gray bars). 72 hours later the cells were stimulated with polyI:C. 
The statistically significant differences are marked with one or two stars, 
which indicate a p value less than 0.01 or 0.0001, respectively. 
 
A similar effect was observed following LPS stimulation (Figure 15), as 
expected. 
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Figure 15. Real-time PCR quantitative analysis of the expression of (ISGs) 
on Mo-mDC was performed. Primary elutriated monocytes were 
differentiated into Mo-mDC and transduced with p30- (red bars) or control 
lentivirus (gray bars). 72 hours later the cells were stimulated with LPS. The 
statistically significant differences are marked with one or two stars, which 
indicate a p value less than 0.01 or 0.0001, respectively. 
4.6.3 Expression of proteins in lentiviruses transduced Mo-mDCs 
upon stimulation with TLR agonists 
To control if these differences observed in the expression of ISGs were 
caused by a different expression of quantity of proteins, we performed and 
immunoblot assay using antibody able to recognize p30 (anti-HA antibody) 
and tubulin as a control. The level of expression of p30 protein was 
comparable in all the conditions tested (Figure 16).  
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Figure 16: Immunoblot analysis of tubulin and p30 expression of the 
experiments presented in Figure 11; 12 and 13. 
 
These data demonstrate that also in ex vivo primary monocytes and in vitro 
primary human dendritic cells, p30 expression inhibits TLR3 and TLR4 
signaling and corroborate the THP-1 cell model.  
4.7 Expression of virus in HTLV-1 infected THP-1 cells with 
different molecular clones (WT or p30-KO) 
To test the contribution of p30 without using over expression systems, we 
infected THP-1 cells with the WT or the p30-KO HTLV-1 molecular clone 
[81] and tested the response of the cells to TLR3 and 4 stimulation (using 
TLR agonists PolyI:C and LPS respectively). The p30-KO HTLV-1, whereby 
the expression of p30 was ablated, produced a lower level of virus as 
measured by the p19 Gag levels released at peak into the supernatant 
when compared to WT (Figure 17, left panel) [81]. Accordingly, a lower 
level of viral DNA was found by quantitative real-time PCR in the cells 
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exposed to p30-KO than the WT with approximately 1 copy per cell versus 
4 copies per cell, respectively (Figure 17, right panel).  
  
Figure 17. THP-1 cells were infected with WT (red line) or p30-KO HTLV-1 
(gray line) virus. Productive infection was monitored by p19 Gag ELISA in 
the cell supernatant (left panel). Uninfected controls were negative for p19 
Gag and are not represented in the graph. HTLV-1 proviral load was 
measured by real-time PCR performed on genomic DNA of THP-1 cells 
infected with WT (red bar) or p30-KO (gray bar) HTLV-1 molecular clones 
(right panel). The normalized value of the HTLV-1 proviral DNA load was 
calculated as HTLV-1 DNA copy number/albumin gene copy number and 
expressed as the number of HTLV-1 proviral DNA copies per 106 cells. 
4.8 Phenotype of HTLV-1 infected THP-1 cells with different 
molecular clones (WT or p30-KO) 
At week 18 post-infection we analyzed the phenotype of infected THP-1 
cells by flow cytometry. Particularly we analyzed the expression of 
activation markers such as HLA-DR, CD80/83 and CD86 and of the homing 
marker CCR7. As we can see from the figure below, even in conditions of 
low levels of virus production the infected cells continued to express high 
levels of the CD80/83, CD86 immune activation markers and the CCR7 
homing marker (Figure 18).  
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Figure 18. Several week post-infection the phenotypes of the THP-1 cells 
infected with WT or p30-KO HTLV-1 and uninfected were analyzed for 
activation markers, such as HLA-DR, CD80/83, CD86 and, the CCR7 
homing marker. 
4.9 Expression of interferon stimulated genes (ISGs) in HTLV-1 
infected THP-1 cells 
At week 19, when viral expression was equivalently low in both cell cultures 
(Figure 17), we stimulated the cells for 6 hours with polyI:C and LPS for 
TLR3 and TLR4, respectively. After stimulation, RNA was extracted and 
tested for ISGs expression. The results are shown as a percentage of 
relative expression of the ISGs in uninfected THP-1 cells versus the WT or 
p30-KO infected THP-1 cells. The response to TLR stimulation was 
significantly inhibited by infection with the WT virus but much less so in 
cells infected with the p30-KO virus upon polyI:C stimulation (Figure 19).  
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Figure 19. ISGs were measured at week 10 post infection, by real-time 
PCR on the RNA from the WT or p30-KO HTLV-1 chronically infected or 
uninfected THP-1 cells following stimulation with polyI:C for 6 hours. The 
statistically significant differences are marked with one or two stars, which 
indicate a p value less than 0.05 or 0.01, respectively. 
 
A similar effect was observed following LPS stimulation (Figure 20), as 
expected. 
 
 106 
 
Figure 20. ISGs were measured at week 10 post infection, by real-time 
PCR on the RNA from the WT or p30-KO HTLV-1 chronically infected or 
uninfected THP-1 cells following stimulation with LPS for 6 hours. The 
statistically significant differences are marked with one or two stars, which 
indicate a p value less than 0.05 or 0.01, respectively. 
4.10 Rescue of viral production and IFN responses in THP-1 cell 
infected with HTLV-1 molecular clone 
4.10.1 Expression of p19 in lentiviruses transduced THP-1 cells 
previously infected with different HTLV-1 molecular clones 
We next investigated whether we could rescue viral expression and IFN 
responses by overexpressing p30 in previously infected cells (week 10 post 
infection) (Figure 17). WT or p30-KO infected THP-1 cells were transduced 
with p30 or mock lentivirus. Un-transduced cells were used as control. After 
2 days, the supernatants were collected and the p19 Gag was analyzed by 
ELISA. Interestingly, p30 expression restored virus production in cells 
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infected with the p30-KO virus (Figure 21).  
 
 
Figure 21. Level of p19 Gag in THP-1 cells chronically infected with WT or 
p30-KO HTLV-1 virus transduced with the lentivirus expressing p30 or the 
control lentivirus. The statistically significant differences are marked with 
one or two stars, which indicate a p value less than 0.05 or 0.005, 
respectively. 
4.10.2 Expression of interferon stimulated genes (ISGs) in lentiviruses 
transduced THP-1 cells previously infected with different HTLV-1 
molecular clones 
Consistent with p30 reducing ISGs expression, RT-PCR analysis of cellular 
mRNA demonstrated that expression of MxA and A3G genes was higher in 
cells infected with p30-KO virus compared to cells infected with WT virus 
(Figure 22).  
Transduction of p30-KO infected cells with lentivirus expressing p30 
rescued only partially the MxA and A3G mRNA expression, suggesting that 
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other viral gene may participate in inhibition of ISG expression (Figure 22).  
 
 
Figure 22. Real-time PCR for the MxA, A3G ISGs genes from the RNAs of 
the infected/transduced cells. The statistically significant differences are 
marked with one or two stars, which indicate a p value less than 0.05 or 
0.005, respectively. 
So we can conclude that p30-KO HTLV-1 virus production and ISGs 
inhibition is rescued by overexpression of p30. 
4.10.3 Expression of proteins in lentiviruses transduced THP-1 cells 
previously infected with different HTLV-1 molecular clones 
Proteins were extracted and tested by Western Blot, to demonstrate 
comparable expression of p30 and GFP (Figure 23). 
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Figure 23. Western Blot analysis for tubulin, p30 or GFP on transduced 
cells. 
4.11 Chromatin immuno-precipitation (ChIP)  
To explore the mechanism by which p30 affects TLR3/4 function, we 
performed a chromatin immuno-precipitation assay. THP-1 cells were p30- 
or mock-transduced with lentivirus. Cells were stimulated for 1 hour with 
specific agonists polyI:C and LPS as a control, then cross-linked. The pull 
downs were performed with antibodies against PU.1, p30-HA, and total 
RNA Pol II, as well as with antibodies specific for the phosphorylated form 
of RNA Pol II CTD-Ser5 or RNA Pol II CTD-Ser2, which respectively 
identify the initiating or the elongating  form of active RNA Pol II. Real-time 
PCR was performed on the ChIP enriched DNA to quantify the amount of 
PU.1 containing transcriptional complexes bound to the promoters of the 
IFNα1, IFNβ, TLR4 and the UbiquitinB genes. We observed that upon 
TLR4 stimulation with LPS and also TLR3 stimulation with polyI:C, lentiviral 
expression of p30 decreased the amount of PU.1 recruited to the IFNα1 
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promoter. We observed also a decrease on the same promoter of both 
initiating and elongating RNA Pol II, as assessed by Pol II-S5 and Pol II-S2 
ChIP (Fig. 24). 
 
Figure 24. ChIP assay was performed on THP-1 cells transduced with p30 
(red bars) or mock transduced (gray bars) lentivirus. Cells were stimulated 
for one hour with LPS or polyI:C (I:C) before the ChIP assay, or not. 
Depicted here, is the relative amount of DNA precipitated with the different 
antibodies normalized on the amount found in the input of the promoters for 
IFNα1 gene. The immunoprecipitations were performed with anti-HA, which 
detect the HA-tagged p30, anti-PU.1, anti-PolIItot, anti-PolIIS5 and anti-
PolIIS2. The data are expressed in terms of nFold, where the unstimulated 
is 1 and represent the amount of promoter DNA for IFNα1 
immunoprecipitated in cells stimulated in the presence or absence of p30. 
The statistically significant differences are marked with one or two stars, 
which indicate a p value minor than 0.01 or 0.0001, respectively. 
 
Moreover, the presence of p30 resulted in a decreased binding of PU.1, Pol 
II-S5 and Pol II-S2 to the promoters of IFNβ and TLR4 upon LPS 
stimulation of TLR4 and polyI:C stimulation of TRL3 (Figure 25). 
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Figure 25. ChIP assay was performed on THP-1 cells transduced with p30 
(red bars) or mock transduced (gray bars) lentivirus. Cells were stimulated 
for one hour with LPS or polyI:C (I:C) before the ChIP assay, or not. 
Depicted here, is the relative amount of DNA precipitated with the different 
antibodies normalized on the amount found in the input of the promoters for 
IFNβ and TLR4 genes. The immunoprecipitations were performed with anti-
HA, which detect the HA-tagged p30, anti-PU.1, anti-PolIItot, anti-PolIIS5 
and anti-PolIIS2. The data are expressed in terms of nFold, where the 
unstimulated is 1 and represent the amount of promoter DNA for IFNβ and 
TLR4 immunoprecipitated in cells stimulated in the presence or absence of 
p30. The statistically significant differences are marked with one or two 
stars, which indicate a p value minor than 0.01 or 0.0001, respectively. 
 
The real time PCR performed on the UbiquitinB promoter, used as control, 
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showed no significant differences, as expected (Figure 26).  
 
 
Figure 26. ChIP assay was performed on THP-1 cells transduced with p30 
(red bars) or mock transduced (gray bars) lentiviral vector. Cells were 
stimulated for one hour with LPS or PolyI:C (I:C) before the ChIP assay, or 
not. Depicted here, is the relative amount of DNA precipitated on the 
amount found in the input of the promoters for UbiquitinB gene, as control. 
The immunoprecipitations were performed with anti-PolIIS5, anti-PolIIS2 
and anti-Poltot antibody. Data are expressed in terms of nFold, where the 
unstimulated is 1 and represent the amount of promoter DNA for the 
UbiquitinB gene immunoprecipitated in cells in the presence or absence of 
p30. Depicted here the ratio of PolS5/Poltot (A) and PolS2/Poltot (B). 
 
All these data are consistent with the reduced expression of IFN responsive 
genes following TLR3 and TLR4 stimulation being mediated by p30 at the 
transcriptional level, as was previously suggested for TLR4 [264].  
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5. CONCLUSIONS AND FUTURE DIRECTIONS 
Interferons (IFNs) are key molecules that mediate antiviral innate immune 
response and are potent regulator of adaptive immune responses since 
they affect immune cell activation, cell growth, and apoptosis. Type I IFNs 
(α and β) are mainly produced by plasmacytoid dendritic cells but also by 
macrophages and fibroblasts [267]. The activation of IFN response leads to 
the upregulation of more than 300 genes (ISGs). These genes encode 
proteins that have antiviral and immunoregulatory activity and are able in 
some cases to suppress viral replication and clear virus [268]. Among 
them, myxovirus resistance GTPase protein A (MxA), 2’, 5’ oligoadenylate 
synthetase (OAS), apolipoprotein B mRNA-editing, enzyme-catalytic, 
polypeptide-like 3G (A3G) exert a particularly important role in the immune 
intracellular response and are considered to be excellent markers for IFN 
action.  
Viruses and often pathogens have evolved a wide variety of strategies to 
counteract and escape the IFN system [267]. The molecular mechanisms 
involved, span from the shutdown of the entire cell metabolism to 
specifically targeting IFN at different levels, such as to inhibit the type-1 
IFN-production itself, to inactivate secreted IFN molecules, to block the 
signaling pathways or the functionality of IFN-induced protein. A variety of 
viruses such as Influenza virus, Sendai virus, Ebola, Herpes simplex virus 
[269], Human Papilloma virus [267], Adenovirus [269], Hepatitis C virus, 
have evolved a way to interfere with specific components of IFN induction 
pathway, mainly by blocking the IFN regulatory factors (IRFs). On the other 
hand, Dengue virus [269], Human Papilloma virus (26), Hepatitis C virus (8) 
and Paramixoviruses [269] target the JAK-STAT pathway. HIV interferes 
with the IFN-induced PKR and A3G through Tat and Vif, respectively (39, 
44).  
HTLV-1 has evolved its own strategy to counteract the IFN system. 
 115 
Although the mechanism is not fully understood, Hishizawa et al. have 
shown that dendritic cells isolated from HTLV-1-infected individuals have 
an impaired ability to secrete type-1 IFN [251]. In addition, it has been 
reported that the cellular protein SOCS, which inhibits STAT1 
phosphorylation, inhibits intracellular signal transduction downstream of the 
IFN receptor, IFNAR1/2, in both ex vivo CD4+ cells from HTLV-1 infected 
individual and in vitro in HTLV-1 infected cells [232]. Moreover, in HTLV-1 
infected cells in vitro the level of phosphorylation of Tyk2 and  17 STAT2, 
two key molecules in the activation cascade of the IFN pathway is 
decreased [265]. Tax also prevents the binding of CBP/p300 with STAT2 in 
a competitive manner. Despite all mentioned above, anti-IFN mechanisms 
evolved by HTLV-1, type-1 IFN maintains a potent antiviral function, and is 
used in the clinic as anti-HTLV-1 therapy [268] in ATL. While IFN-α 
treatment alone results in a modest and transient, although appreciable, 
beneficial effect on ATL patients, when combined with zidovudin (AZT) and 
arsenic trioxide it causes long lasting remission [251]. The mechanisms 
underlying this therapeutic effect, remains unclear. In fact, while some 
groups demonstrated in vitro that the treatment with IFN-α decreases 
HTLV-1 expression, Kannagi’s group showed that the p19 Gag released in 
the supernatant is decreased, but not the expression of other viral genes 
[253]. However, the addition of AZT decreases viral transcription, p19 Gag 
and Tax production, leaving the p53 dependent apoptotic pathways 
unaffected and restoring the PKR antiviral activity [253].  
Here, we demonstrate that HTLV-1 has evolved additional mechanisms to 
counteract the IFN system through the interaction of the viral regulatory 
protein p30 and the myeloid transcription factor PU.1.  
In this study we found that HTLV-1 p30 decreases TLR4 expression in 
response to PMA stimulation in p30-LV transduced THP-1 cells. We 
confirmed that the mechanism underlying this effect of p30 was 
transcriptional. Moreover we showed that p30 decrease the expression of 
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intracellular cytokines TNF-α and IL-12 after LPS stimulation. These data 
are consistent with the finding of Datta and colleagues [264], which 
demonstrated that p30 decreases the release of pro-inflammatory 
cytokines, such as TNF-α, IL-8, and MCP1 upon stimulation with the TLR4 
specific agonist lipopolysaccharide (LPS) by decreasing the expression of 
TLR4 itself. 
Moreover, we demonstrated that p30 decreases TLR3 induction of 
interferon stimulated genes (ISGs) expression in THP-1 cells, but not of 
TLR7/8. Similar results were obtained in primary human monocytes and 
monocyte-derived dendritic cells (Mo-mDCs). Moreover the ablation of p30 
from an HTLV-1 molecular clone results in decreased inhibition of TLR3 
and TLR4 inducted ISGs expression in THP-1 cells that is partly restored 
by p30 overexpression. Finally our data demonstrated that p30-KO HTLV-1 
virus production and ISGs inhibition is rescued by overexpression of p30. 
Because p30 regulates the expression of other viral RNAs, it is still 
debatable whether p30 acts directly or other viral proteins are involved in 
decreasing ISGs. However, the ChIP assay we performed and the rescued 
inhibition of the ISGs upon p30 overexpression suggests a direct interaction 
between p30 and PU.1. This is consistent with the observations reported by 
Datta and colleagues [264]. To address the role of other viral proteins, 
detailed analysis of the viral expression pattern in the p30-KO mutant 
versus WT infected cells needs to be done.  
We are currently investigating the expression level of viral transcripts and 
the differential expression of these in monocytes versus CD4+ T-
lymphocytes. Indeed, we found that after the initial peak of p19 Gag in the 
supernatant around day 10, the virus production drops to low level of 
expression in THP-1 (Figure 17). Preliminary data, not included in this 
thesis, shows that in THP-1 cells the total mRNA level of hbz is higher than 
tax/rex message during chronic infection. Together this suggests that in 
monocytes the regulation of viral transcription might follow a different 
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pattern. The effect of p30 is pivotal to allow infectivity and persistence, as 
demonstrated by in vivo experiments in macaques [81]. Our data 
demonstrates that in the presence of p30 the interferon response is 
abrogated during viral replication. Thus, strategies aimed at silencing the 
expression of p30 with siRNA in conjunction with other approaches may 
further curtail viral replication and possibly contribute to the eradication of 
infected cell through innate IFN mediated immune responses.  
This work allowed us the possibility to write and publish a paper on Journal 
of Virology [270]. 
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